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INTRODUCTION 
A better understanding of the physiological and functional changes that occur with aging will 
enable to improve strategies for treating elderly cancer patients. For istance, hemathological toxicity 
is a major obstacle to the administration of chemotherapy in elderly cancer patients and ageing per 
sé is a major risk factor for cancer development, but the age-related impairment of immune system 
has never been studied in cancer patients.  
For this reason, the present Doctoral Course has been committed to provide the first description of 
immune senescence observed in cancer patients. In the context of a prospective, exploratory study, 
TREC levels, subsets of peripheral naïve/memory T-cells and peripheral cell telomere length have 
been detected in elderly cancer patients and in age-matched controls. 
A further critical issue of geriatric oncology is to uncover clinical problems that may impair the 
potential benefits and tolerability of anticancer treatments (Balducci, 2003; Extermann, 2003).  
Recently, the International Society of Geriatric Oncology released a position paper where the 
obligatory integration of a comparable form of geriatric assessment is strongly recommended in 
future studies (Wildiers, 2013). The Multidimensional Prognostic Index (MPI) has been developed 
from a complete CGA and, differently from it, MPI may be administered and scored in a consistent 
manner. In order to answer this prioritary issue of geriatric oncology, the second project of this 
doctoral research program has been devoted to validate the MPI in patients with advanced cancer 
(Pilotto, 2008) to predict the 6 and 12-months overall mortality risk. In addition to estimate the 
tumor-independent survival, a CGA is essential when planning a cancer treatment as it uncovers 
medical conditions that may worsen the chemotherapy toxicity reported in clinical trials involving 
younger patients (Balducci, 2007). Despite there is strong evidence that any treatment decision in 
elderly cancer patients should be supported by a CGA, this is still performed in less than 10% of 
cancer centers because it is  highly time-consuming. For this reason various author attempted to 
summarize the complete CGA in shorter versions. Among these screening tests, the Vulnerable 
Elders Survey (VES-13), a simple 13-item questionnaire has good sensitivity and acceptable 
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specificity (Luciani, 2010) in comparison with a full CGA, but there is not consistent medical 
literature regarding its ability to predict chemotherapy toxicity. Therefore, the third chapter of the 
present Doctoral Research Program reports a joint analysis of 4 prospective studies that evaluated 
the accuracy of VES-13 in predicting the risk of high grade toxicity in elderly patients undergoing 
chemotherapy.  
 
PATIENTS AND METHODS. 
Immunesenescence and Cancer.  Fifty-two elderly patients with breast or colorectal cancer and 39 
age-matched controls without personal history of cancer were enrolled. All patients underwent a 
Comprehensive Geriatric Assessment (CGA), from which a multidimensional prognostic index 
(MPI) score was calculated. Peripheral blood samples were collected at the time of enrollment, prior 
to any oncological medical treatment (endocrine therapy, chemo- therapy, radiotherapy or immune 
therapy). Peripheral blood samples were studied for naïve and recent thymic emigrant (RTE) CD4+ 
and C8+ cells by flow cytometry. T-cell receptor rearrangement excision circle (TREC) levels, 
telomere length and telomerase activity in peripheral blood cells were quantified by real-time PCR. 
In addition to descriptive analysis through Mann–Whitney U test and Student's t-test, correlations 
between age and TREC levels, or telomere length in both groups were analyzed with Pearson's χ2 
test. TREC levels and telomere length were also analyzed as dichotomous variables (cut-off: 
≤median) and Odd Ratios were estimated with a logistic regression model. 
Validation of MPI in Cancer Patients. Patients aged 70 yrs and older with a recently-diagnosed 
metastatic or inoperable cancer were enrolled and received a complete CGA including functional 
state, comorbidity, cognitive and humoral state, nutritional state, risk of pressure scores, social 
aspect and medications. The MPI score was calculated for each patient from the results of the 
various tests (ADL, IADL, SPMSQ, CIRS-CI, MNA, ESS, number of drugs, and social conditions), 
as reported elsewhere by Pilotto et al (Pilotto, 2007).  
 4 
Statistical Analysis. The associations between 6- or 12-months mortality and the MPI scores, was 
analyzed using a Cox’s proportional hazards regression model adjusted for age and gender. Hazard 
ratios (HR) and 95% confidence intervals (CI) were calculated to estimate the strength of the 
associations. The discriminatory power of the mortality model at 6 and 12 months of follow-up was 
assessed by calculating the area under the ROC curves for the MPI (considered as a continuous 
variable) using logistic regression models. 
VES-13 to predict chemotherapy toxicity. The study involved patients aged >70 years with a 
diagnosis of a solid or hematological tumor. All Patients were administered VES-13. For all 
patients number of medications, comorbidities, CIRS-G score and index, type of chemotherapy, line 
of treatment, MMSE and MNA scores were recorded. Grade 3-4 hematological and non 
hematological toxicities were avaibile for all patients. Regression analysis was performed. 
 
RESULTS 
Immunesenescence and Cancer. The percentages of CD8+ naïve and CD8+ RTE cells and TREC 
levels were significantly lower in cancer patients than in controls (p = 0.003, p = 0.004, p = 0.031, 
respectively). Telomere lengths in peripheral blood cells were significantly shorter in cancer 
patients than in controls (p = 0.046) and did not correlate with age in patients, whereas it did in 
controls (r = −0.354, p = 0.031). Short telomere (≤median)/low TREC (≤median) profile was 
associated with higher risk of cancer (OR = 3.68 [95% CI 1.22–11.11]; p = 0.021). Neither 
unfitness on CGA nor MPI score were significantly related to thymic output or telomere length in 
either group. 
Validation of MPI in Cancer Patients. A hundred and sixty patients entered the study. The MPI-
related hazard ratios were higher at 6 months of follow-up than at 12 months, a high MPI being 
associated with a HR of 8.094 (95% CI 3.749-17.475, p<0.0001) at 6 months as opposed to 5.655 
(95% CI 2.866-11.158, p<0.0001) at 12 months. When the MPI was considered as a continuous 
variable, any increase by 0.2 units (corresponding to the lower quartile) was associated with a 
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2.347-fold increase in the mortality risk (95% CI=1.838-2.997) at 6 months and a 2.051-fold 
increase (95% CI=1.662-2.531) at 12 months. The discriminatory power of the MPI’s predictive 
performance was statistically significant. 
The age- and sex-adjusted area under the ROC curve for MPI score at 6 and 12 months of follow-up 
were 0.81 (95% CI, 0.74-0.88) and 0.78 (95% CI, 0.71-0.85), respectively. 
VES-13 to predict chemotherapy toxicity. 648 patients aged ≥ 66 years old were included, mean 
age was 76.2 years (SD 4.5, 66 to 90), 336 (51.9%) were female. VES-13 identified 287 of the 
patients (44.3%) as vulnerable. Grade 3-4 hematological and non-hematological toxicities were 
more prevalent in the vulnerable subjects (35.2% vs 20.8%, p <0.0001, and 18.5% vs 10.8%, p = 
0.0055). Vulnerable patients (OR) had a higher risk of hematological and non hematological 
toxicity with an OR 2.15, (95% CI 1.46-3.17; p<0.001) and 1.66 (95% CI 1.02-2.72; p = 0.043) 
respectively. 
 
CONCLUSIONS 
 
The study of Immunesenescence provided the first evidence that elderly cancer patients seemed to 
suffer from a more severe decline in thymic output and had a lower proportion of naïve CD8+ cells 
than age-matched controls. In addition, cancer patients had significantly shorter telomeres in their 
peripheral blood cells than  age-matched non-cancer patients. This result suggests the unpublished 
hypothesis – which would need to be tested in a larger study - that elderly people with shorter 
telomeres are at higher risk of developing cancer. If confirmed, thymic output and telomere length  
could be widely used in elderly general population to easily identify subjects who run an higher risk 
of developing cancer and optimize the resources for screening procedures. 
The second trial was the first to validate MPI in the oncological setting. The MPI retained in elderly 
patients with advanced cancer the same reliability and accuracy as reported in the original study by 
Pilotto et al. The results also suggested the possibility of creating a new, better-performing version 
of MPI by integrating it with the comorbidity severity index and the geriatric depression scale.  
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In the third study the patients identified as vulnerable by the VES-13 had a statistically significant 
higher risk of developing both hematological and non-hematological toxicity. These risk increases 
progressively with the aging of the population, particularly for haematological toxicity. 
With the awareness that geriatric assessment of cancer patients cannot relies on a single test, future 
studies should be planned with the aim of prospectively identifying which is the most appropriate 
geriatric instrument for any single aspect of patient management (e.g. toxicity, overall survival, 
active life expectancy, or the quality of life) and clinical research.  
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INTRODUZIONE 
Nonostante i casi di neoplasie solide nell’anziano siano in aumento, da decenni gli anziani sono 
sistematicamente esclusi dagli studi clinici in oncologia e questo implica una notevole difficoltà per 
gli oncologi a trasferire ai pazienti ultrasettantenni i risultati delle ricerche terapeutiche 
oncologiche.  
Solo una migliore conoscenza delle modificazioni fisiologiche e funzionali che si accompagnano 
all’invecchiamento consentirebbe di migliorare le strategie di trattamento dei pazienti anziani con 
tumore. In particolare, nonostante la tossicità ematologica rappresenti il principale ostacolo alla 
somministrazione di chemioterapia e l’età avanzata sia di per sé un fattore di rischio per 
l’oncogenesi, non esiste in letteratura alcuno studio che abbia affrontato l’immunosenescenza nel 
paziente oncologico anziano. Perciò, parte considerevole dell’attività di ricerca svolta nel presente 
programma di Dottorato è stata dedicata ad uno studio prospettico di ricerca translazionale che ha 
confrontato l’output timico (livelli di T-cell receptor rearrangement excision circle – TREC- e 
subset di cellule T naïve e memoria) e la lunghezza dei telomeri in sangue periferico in una coorte 
di pazienti ultrasettantenni con diagnosi di neoplasia mammaria o colorettale con quelli riportati in 
anziani di pari età senza anamnesi personale di neoplasia. 
Un’altra criticità dell’Oncologia Geriatrica è quella di standardizzare la valutazione geriatrica 
multidimensionale (CGA), strumento fondamentale per identificare possibili ostacoli all’efficacia 
ed alla tollerabilità dei trattamenti oncologici, per poterla utilizzare negli studi clinici. 
Per rispondere a tale richiesta il secondo progetto di questo programma di Dottorato è stato 
finalizzato a validare per la prima volta nel setting oncologico il Multidimensional Prognostic Index 
(MPI), uno strumento codificato che deriva dalla CGA tradizionale. Nell’ambito di uno studio di 
Ricerca Ministeriale Finalizzata è stata valutata la capacità del MPI di predire la mortalità a 6 e 12 
mesi in una coorte di pazienti anziani con neoplasia solida avanzata.  
Terza priorità dell’oncologia geriatrica è di diffondere maggiormente l’uso della valutazione 
geriatrica. Attualmente infatti meno del 10% dei centri oncologici applica la CGA, che richiede 
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oltre 2 ore a paziente per la corretta esecuzione, mentre invece qualsiasi scelta terapeutica nel 
paziente anziano dovrebbe tenere conto di una CGA basale, anche allo scopo di identificare i 
pazienti a rischio di tossicità da chemioterapia. Per risolvere questa criticità negli ultimi anni sono 
stati introdotti dei test di screening fnializzati ad identificare i pazienti che meritano una valutazione 
geriatrica. Tra questi, la Vulnerable Elders Survey – 13 (VES-13) presenta una buona sensibilità e 
specificità rispetto alla CGA completa ma non era mai stata testata per predire la tossicità da 
chemioterapia. Pertanto, nel terzo studio riportato nella presente tesi sono stati analizzati i risultati 
di 4 studi prospettici che hanno valutato l’accuratezza della VES-13 nel predire il rischio di tossicità 
di alto grado in pazienti oncologici anziani in trattamento antiblatico.  
 
PAZIENTI E METODI. 
Immunesenescenza e Cancro.  Cinquantadue pazienti con neoplasia mammaria o colorettale in 
stadio I-III e 39 controlli senza storia personale di tumore e di pari età sono stati arruolati nel 
presente studio e sottoposti inizialmente a CGA. Dopo la chirurgia e prima di iniziare qualsiasi 
trattamento medico adiuvante è stato prelevato sangue periferico per la determinazione 
citofluorimetrica di CD4+ and C8+ naïve e memoria e per la determinazione in real-time PCR dei 
livelli di TREC, della lunghezza dei telomeri nelle cellule periferiche e dell’attività telomerasica.  
Validazione del MPI in pazienti oncologici. Pazienti ultrasettantenni e con recente diagnosi di 
neoplasia solida metastatica o inoperabile sono stati arruolati e sottoposti ad una CGA completa, 
comprendente lo stato funzionale, cognitive, umorale, le comorbidità, le medicazioni a domicilio, lo 
stato nutrizionale, il rischio di piaghe da decubito, gli aspetti sociali, da cui è stato calcolato il MPI 
come riportato da Pilotto et al (Pilotto, 2007). Per definire il valore prognostico di MPI sono stati 
utilizzati modelli di regressione Cox aggiustati per età e genere. Sono state inoltre calcolate le curve 
ROC attraverso modelli di regression logistica. 
VES-13 e rischio di tossicità da chemioterapia. Quest’analisi combinata ha coinvolto pazienti 
ultrasettantenni con diagnosi di neoplasia solida o ematologica. Tutti i pazienti hanno compilato il 
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questionario VES-13. Sono stati riportati infine I dati relative al tipo di chemioterapia ricevuta, la 
linea di trattamento, la tossicità ematologica e non ematologica di grado 3-4 secondo I common 
toxicity criteria for adverse events (CTCAE). A questi dati è stata applicata un’analisi di 
regressione.  
 
RISULTATI 
Immunosenescenza e Cancro. La percentuale di cellule CD8+ naïve, CD8+ RTE ed i livelli di 
TREC sono risultati significativamente più bassi nei pazienti oncologici rispetto ai controlli (p = 
0.003, p = 0.004, p = 0.031, rispettivamente). La lunghezza dei telomeri nelle cellule di sangue 
periferico era significativamente inferiore nei pazienti oncologici rispetto ai controlli (p = 0.046) e 
non correlava con l’età, come avveniva invece nei controlli (r = −0.354, p = 0.031). Il profilo con 
telomero corto (inferiori alla mediana) e bassi livelli di TREC (inferiori alla mediana) era 
significativamente associato con la diagnosi di neoplasia (OR = 3.68 [95% CI 1.22–11.11]; p = 
0.021) mentre non vi era alcuna correlazione tra l’esito della CGA ed il punteggio MPI da un lato 
ed i marcatori di immunosenescenza dall’altro in entrambi i gruppi.  
Validazione del MPI in pazienti oncologici. Lo studio ha coinvolto 160 pazienti. Gli hazard ratio 
correlati a MPI sfavorevole sono risultati significativamente più alti per la mortalità a 6 mesi 
rispetto a 12 mesi, più precisamente 8.094 (95% CI 3.749-17.475, p<0.0001) a 6 mesi e 5.655 (95% 
CI 2.866-11.158, p<0.0001) a 12 mesi. Quando MPI è stato valutato come una variabile continua, 
ogni incremento di 0.2 unità era associato ad un aumento di 2.347-volte del rischio di mortalità 
(95% CI=1.838-2.997) a 6 mesi e 2.051-volte (95% CI=1.662-2.531) a 12 mesi. Il valore 
prognostico di MPI è risultato statisticamente significativo. L’area delle curve ROC a 6 e 12 mesi, 
aggiustate per genere ed età era 0.81 (95% CI, 0.74-0.88) e 0.78 (95% CI, 0.71-0.85), 
rispettivamente. 
VES-13 e rischio di tossicità da chemioterapia. Seicentoquarantotto pazienti di età ≥ 66 anni sono 
stati considerati nella presente analisi. Attraverso la VES-13 sono stati identificati 287 pazienti 
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vulnerabili. Gli eventi di tossicità ematologica e non ematologica di grado 3-4 sono risultati 
prevalenti nei soggetti vulnerabili (35.2% vs 20.8%, p <0.0001, e 18.5% vs 10.8%, p = 0.0055). Gli 
odd ratios per la tossicità ematologica e non ematologica nei pazienti vulnerabili sono risultati pari a 
2.15, (95% CI 1.46-3.17; p<0.001) e 1.66 (95% CI 1.02-2.72; p = 0.043) rispettivamente. 
 
CONCLUSIONI 
 
Lo studio sull’immunosenescenza e cancro ha fornito la prima evidenza che i pazienti anziani 
oncologici, rispetto ai controlli sani, presentano una severa riduzione dell’output timico e della 
lunghezza dei telomeri in cellule di sangue periferico. Tali risultati suggeriscono l’ipotesi che i 
soggetti anziani con sistema immunitario senescente e telomeri più corti abbiano un rischio più alto 
di sviluppare neoplasie. Se tale associazione fosse confermata in una popolazione più ampia, i 
marcatori di immunosenescenza potrebbero essere impiegati per identificare gli anziani a rischio più 
elevato di neoplasia, sui quali concentrare le risorse per la diagnosi precoce.  
Il secondo studio riportato è stato il primo a dimostrare che nei pazienti oncologici MPI mantiene il 
suo valore prognostico, con la stessa affidabilità ed accuratezza riportate nello studio originale di 
Pilotto et al. I risultati dello studio suggeriscono infine la possibilità di migliorare le prestazioni di 
MPI in oncologia integrandolo con l’indice di comorbidità e lo stato umorale.   
Il terzo studio ha dimostrato che i pazienti giudicati vulnerabili alla VES-13 hanno un rischio 
significativamente più alto di sviluppare tossicità ematologica e non ematologica di alto grado. Tale 
rischio aumenta progressivamente con l’età, soprattutto per la tossicità eamtologica.  
Con la consapevolezza che la valutazione geriatrica del paziente oncologico anziano non può essere 
esaustivamente svolta con un unico test, ulteriori studi dovranno essere condotti per identificare i 
test più appropriati per altri aspetti rilevanti per la gestione del paziente con neoplasia, ovvero la 
l’aspettativa di vita tumore-indipendente e la qualità di vita.  Parallelamente vi è la necessità di 
studiare il processo di invecchiamento nell’anziano oncologico per identificare dei marcatori 
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molecolari di età biologica, che guidino in maniera oggettiva la scelta terapeutica in questa 
popolazione. 
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Persons over the age of 65 years are the fastest growing segment of the population and will account 
for an estimated 20% of Americans and 25% of Europeans by the year 2030 (Fries, 2003).  
Cancer incidence is 11-fold higher in persons over the age of 65 years than in younger ones so that 
the number of incident cases of cancer in the elderly is expected to significantly increase in next 
decades (American Cancer Society, 2012). 
Despite approximately 70% of deaths from cancer occur in patients aged 65 and over (Jemal A, 
2010), the majority of clinical trial research in cancer care is conducted in younger patients 
(Hutchins, 1999). This discrepancy creates uncertainty for oncologists when extrapolating available 
data to treat their older patients. As result, elderly patients are less likely to be treated according to 
guidelines and their under-treatment may be detrimental to both survival and quality of life, as 
reported in several studies (Sargent, 2001; Bouchardy, 2003; Dale, 2003). 
A better understanding of the physiological and functional changes that occur with aging will 
enable to improve strategies for treating elderly cancer patients. Since the aging process coincides 
with a gradual decline in the functional reserve of multiple organ systems (Balducci, 2003) the 
search for laboratory markers of biological aging and organ reserve should be a priority of research 
in the field of geriatric oncology. 
Despite hemathological toxicity is a major obstacle to the administration of chemotherapy in elderly 
cancer patients, the age-related impairment of immune system has never been studied in cancer 
patients.  
For this reason, the present Doctoral Course has been committed to provide the first description of 
immune senescence observed in cancer patients. In the context of a prospective, exploratory study, 
TREC levels, subsets of peripheral naïve/memory T-cells and peripheral cell telomere length have 
been detected in elderly cancer patients and in age-matched controls. 
A further critical issue of geriatric oncology is to uncover clinical problems that may impair the 
potential benefits and tolerability of anticancer treatments (Balducci, 2003; Extermann, 2003).  
Really, the comprehensive geriatric assessment (CGA), a panel of clinical tools exploring physical, 
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humoral and cognitive impairment, concomitant diseases, medications and social state, is the only 
instrument available for oncologists to estimate tumour independent life-expectancy, uncover 
potential contraindications to antiblastic treatment and detect causes of additional risk of severe 
chemotherapy toxicity in elderly cancer patients (Extermann, 2005).  
In the last decades, a large variety of CGAs was developed but none of them was chosen as 
reference, universally accepted, CGA model. Consequently, results by different studies cannot be 
compared and many outcomes that are of interest to older patients, such as functional impairment 
and independence, are not evaluated in traditional clinical trials (Falci, 2010). 
Recently, the International Society of Geriatric Oncology released a position paper where the 
obligatory integration of a comparable form of geriatric assessment is strongly recommended in 
future studies (Wildiers, 2013). The Multidimensional Prognostic Index (MPI) has been recently 
developed from a complete CGA and, differently from it, MPI may be administered and scored in a 
consistent manner. In order to answer a prioritary issue of geriatric oncology, the lack of a largely 
accepted, standardized model of geriatric assessment, the second project of this doctoral research 
program has been devoted to validate the MPI in patients with advanced cancer (Pilotto, 2008).   
In addition to estimate the tumor-independent survival, a CGA is essential when planning a cancer 
treatment as it uncovers medical conditions that may worsen the chemotherapy toxicity reported in 
clinical trials involving younger patients (Balducci, 2007). Despite there is strong evidence that any 
treatment decision in elderly cancer patients should be supported by a CGA, this is still performed 
in less than 10% of cancer centers because of the shortage of economic resources. In fact, CGA is  
highly time-consuming. For this reason various author attempted to summarize the complete CGA 
in shorter versions. These screening tools should distinghish fit patients, who deserve the same 
treatments of   younger adults, from vulnerable patients, who need a full CGA (Overcash, 2004; 
Molina-Garrido, 2011; Hurria, 2011). Among these screening tests, the Vulnerable Elders Survey 
(VES-13), a simple 13-item function-based self-report questionnaire that has been developed and 
validated in a population of 6,000 community-dwelling U.S. Medicare beneficiaries aged 65 and 
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older, warrants the best performance to identify people at increased risk of death or functional 
decline (Saliba, 2001; Mohile, 2007).  
In comparison with a full CGA, VES-13 has good sensitivity and acceptable specificity (Luciani, 
2010), but there is not consistent medical literature regarding its ability to predict chemotherapy 
toxicity. Therefore, the third chapter of the present Doctoral Research Program reports the first 
prospective study that evaluated the accuracy of VES-13 in predicting the risk of high grade toxicity 
in elderly patients undergoing chemotherapy.  
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BACKGROUND AND AIMS 
People over 65 years old are the fastest-growing age bracket in the population and will account for 
an estimated 20% of Americans and 25% of Europeans by the year 2030 (Fries, 2003). The 
incidence of malignancies increases with age, so the number of cancers in the elderly is expected to 
increase significantly in years to come (American Cancer Society, 2012).  Data are becoming 
available that will enable a better use of chemotherapy in the older patient population (Hurria, 
2012), but several studies have shown that elderly patients are less likely to be treated according to 
the guidelines, and their undertreatment can have a detrimental effect on both survival and quality 
of life (Bouchardy, 2003; Dale, 2003). Some studies have shown  that elderly cancer patients may 
benefit from chemotherapy just as much as younger adults (Sargent, 2001; Muss, 2005), but at a 
higher risk of hematological toxicity (Muss, 2007). A better understanding of the physiological and 
functional changes that occur with aging will enable useful strategies for treating elderly cancer 
patients to be developed. Since the ageing process coincides with a gradual decline in the functional 
reserve of multiple organ systems (Balducci, 2003), the assessment of elderly cancer patients should 
not be based on their clinical features alone. The search for laboratory markers of biological aging 
and organ reserve should be a priority of clinical research in the field of geriatric oncology.  
 
Over a lifetime, the immune system undergoes a profound remodeling process with a major impact 
on health and survival (Grubeck-Loebenstein, 2009; Fulop, 2010). Thymic involution and a 
diminished output of T lymphocytes are thought to be among the major factors contributing to the 
loss of immune function with age (Berzin, 1998). T cell output begins to decline exponentially from 
early on (Doeuk, 1998; Naylor, 2005) and by the a person reaches 75 years of age their immune 
repertoire appears to be severely impaired (Naylor, 2005). Recent data suggest, however, that the 
thymus may remain active even late in life, supplying functional T cells to the periphery (Nasi, 
2006; Mitchell, 2010).  
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Measuring T cell receptor rearrangement excision circle (TREC) levels in peripheral blood 
lymphocytes has been suggested as a method for quantifying thymic output in different conditions 
(Douek, 1998; Zang, 1999; Ometto, 2002; De Rossi, 2002). TRECs are generated by T cell receptor 
gene rearrangement (Breit, 1997) and are  maintained in thymic emigrant cells as DNA episomes. 
Because TRECs are not duplicated during mitosis, their concentration is diluted out with each cell 
division. The frequency of recent thymic emigrant (RTE) cells in peripheral blood, identified by the 
marker CD31+ among the CD45RA+ naïve T cells (Kimmig, 2002), decreases with aging and 
correlates well with the decline in TREC levels (Kohler, 2005; Junge, 2007). It has also been 
estimated, using a mathematical model describing human thymopoiesis, that the number of TREC-
positive cells released every day from the thymus into the peripheral blood drops exponentially by 2 
orders of magnitude during an 80-year lifespan (Ye, 2002).  
Very little is known about the relationship between TRECs and cancer, especially in elderly patients. 
One study on patients with head and neck cancers, including just a few ≥70 years old, showed  that 
the age-associated decrease in TREC-positive cells  and naive CD8+ and CD4+ T cells was 
significantly greater in cancer patients than in controls, thus suggesting an altered lymphocyte 
homeostasis in cancer patients (Kuss, 2005). 
 
Immune senescence affects the B-cell compartment too. A declining availability of T cell help 
and/or innate immune function could also contribute to changes in the B-cell compartment, 
interfering with B lymphopoiesis and homeostasis. These changes may ultimately exacerbate the 
decline in the protective qualities of antibodies produced by the elderly, increasing their sensitivity 
to infections and likelihood of developing cancer and some autoimmune syndromes (Sasaki, 2011). 
Whether  aging leads to changes in serum immunoglobulin levels is still a matter of debate.  
Immune system function depends largely on its capacity for extensive cell division and clonal 
lymphocyte expansion. Telomere length, and its regulation by telomerase have attracted 
considerable attention for their potential roles in controlling cell replication (Greider, 1998). 
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Telomeres are capping end structures of eukaryotic chromosomes essential for protecting 
chromosome integrity (Blackburn, 1991); they comprise a non-coding sequence of (TTAGGG)n 
repeats, in complex with the shelterin  proteins (de Lange, 2009). Telomeres gradually become 
shorter with each cell division due to the inability of DNA polymerase to fully replicate the 3’ ends 
of DNA. When a critical length is reached the cell undergoes cycle arrest and apoptosis (Blasco, 
2005). Permanent cell growth relies on telomere maintenance and certain human cell subsets, as 
well as most cancer cells, have a telomerase activity that enables telomere elongation (Dolcetti, 
2012). Despite their telomerase activity, most tumor cells have shorter telomeres than the 
corresponding normal tissues, and there is a relationship between short telomeres and genetic 
instability (Rampazzo, 2010; Garcia-Aranda, 2006). 
 
Since telomere shortening reflects cell turnover and exposure to oxidative and inflammatory 
damage, which are crucial processes of biological aging, it has been suggested that telomere length  
may serve as an indicator of the aging process (Wong, 2003; Aviv 2006; Baird , 2006). Telomere 
shortening in peripheral blood cells has been associated with a number of chronic diseases, such as 
coronary heart disease, hypertension, dementia, obesity, insulin resistance, and osteoporosis. On the 
other hand, two clinical trials failed to confirm any relationship between telomere length and frailty 
syndrome in elderly non-cancer patients (Woo, 2008; Colerton, 2012).  
Short telomeres in peripheral blood cells have been associated with a higher risk of head and neck, 
lung, breast, colorectal, bladder and renal cell cancer (Wu, 2003; Shao, 2007; Svenson, 2008). 
Telomere length in peripheral blood cells has also been independently associated with cancer-
specific survival in patients with metastatic breast cancer, suggesting that this marker may be 
prognostic for overall survival in cancer patients generally (Svenson, 2008). To date, however, 
telomere length in peripheral blood cells has been measured in elderly non-cancer patients and in 
younger cancer patients, but not in elderly cancer patients.  
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Here we present the results of a prospective observational study that aimed to provide the first 
description of immune senescence markers (TREC levels, subsets of peripheral naïve and memory 
T-cells, interleukin (IL)-6 and immunoglobulin levels), telomere length and frailty scores in a 
sample of elderly cancer patients and age-matched controls.  
 
1.2 PATIENTS AND METHODS 
1.2.1 Study design and study population 
This was a mono-institutional, exploratory study. Co-primary endpoints were to establish whether 
TREC levels and telomere lengths differ significantly between cancer patients and age-matched 
controls. The secondary endpoint was to assess the age effect on TREC levels and telomere lengths 
in both cancer patients and age-matched controls. 
Patients aged ≥70 years diagnosed during the previous 2 months with stage I-III breast or colorectal 
cancer, and radically resected, who were consecutively admitted to the Oncology Division of the 
Veneto Institute of Oncology, were considered for enrolment in the study. Controls included 
patients ≥70 years old with no personal history of cancer, consecutively admitted to the Geriatric 
Clinic at Padova University. For both groups, the exclusion criteria were: any hematological 
disorders (also regarding the erythropoietic and myelocytic lines), chronic diseases requiring 
continuous immunosuppressive treatment (rheumatological disorders, autoimmune conditions, etc.), 
prior immunodeficiency, blood transfusion ≤4 weeks before blood sampling, active infectious 
diseases, extremely severe comorbidities suggesting a life expectancy <6 months, severe cognitive 
impairments hampering communication with the physician. 
The study was approved by the Institutional Ethics Committee and conducted in accordance with 
the Helsinki Declaration and Good Clinical Practice guidelines. Written informed consent was 
obtained from all patients. 
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1.2.2 Clinical assessment 
Complete demographic and clinical details were collected at the baseline for each patient (date of 
birth, gender, formal education, weight, height, body mass index (BMI), personal medical history, 
current medication; plus information, for cancer patients, about the primary tumor site, histotype, 
and stage, and any oncological treatment planned). Concomitantly with the first visit, both cases 
and controls underwent a traditional comprehensive geriatric assessment (CGA) administered by a 
multidisciplinary team that included a medical oncologist, a geriatrician and a psychologist. As 
reported elsewhere (Basso, 2004), the CGA included Activities of Daily Living (ADL) (Katz, 1970), 
Instrumental Activities of Daily Living (IADL) (Lawton, 1969), the Short Portable Mental Status 
Questionnaire (SPMSQ) (Pfeiffer, 1975) and the Mini Mental Status Examination (MMSE) 
(Folstein, 1975). Comorbidities and their severity were investigated using the Cumulative Illness 
Rating Scale-Comorbidity Index (CIRS-CI) and the Cumulative Illness Rating Scale-Severity Index 
(CIRS-SI) (Conwell, 1993). Affective status was assessed with the Geriatric Depression Scale 
(GDS) (Yesavage, 1983). Nutritional status was explored with the Mini Nutritional Assessment 
(MNA) (Guigoz et al, 1999). The risk of developing pressure sores was tested with the Exton Smith 
Scale (ESS) (Bliss, 1966). Social aspects included household composition, institutionalization, 
amount of assistance provided by a caregiver (average number of hours per day). The number of 
different drugs taken by patients for concomitant diseases was also recorded. The results of the 
CGA were interpreted as previously reported by Balducci (Balducci, 2003), classifying patients as 
fit, vulnerable or frail. To report the final outcome of the CGA in the form of a continuous variable, 
a multidimensional prognostic index (MPI) score was also calculated for each patient based on 
findings for the ADL, IADL, SPMSQ, CIRS-CI, CIRS-SI, MNA, ESS, number of drugs and social 
conditions, assuming a low mortality risk for MPI ≤0.33, a moderate risk for MPI between 0.34 and 
0.66, and a high risk for MPI >0.66 (Pilotto, 2008). 
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1.2.3 Biomarker analyses 
Peripheral blood samples were collected at the time of enrolment and analyzed for the standard 
blood parameters (listed in Table 1C), and for the following tests. 
 
1.2.4 Flow cytometry 
Peripheral blood mononuclear cells (PBMC) were isolated from peripheral blood by centrifugation 
on a Ficoll-Paque (Pharmacia, Uppsala, Sweden) gradient. Approximately 250 000 PBMC were 
stained for 15 min in the dark using the following labeled monoclonal antibodies (mAbs): anti-CD3 
(fluorescein isothiocyanate [FITC]), anti-CD4 (peridinin chlorophyll protein [PerCP]), anti-CD8 
(PerCP), anti-CD31 (phycoerythrin [PE]) and anti-CD45RA (allophycocyanin [APC]). Appropriate 
isotypic controls (mouse IgG1-PE and mouse IgG2b-APC) were used to assess non-specific 
staining. All mAbs were purchased from Becton-Dickinson (Becton-Dickinson Biosciences 
Pharmingen, San Diego, CA, USA). Cells were then washed with Automacs Buffer (Miltenyi 
Biotec Inc., Auburn, CA, USA) and resuspended in PBS supplemented with 1% paraformaldehyde. 
All samples were analyzed by four-color flow cytometry using a fluorescence-activated cell sorter 
(FACS) Calibur (Becton-Dickinson) equipped with a 488 nm argon-ion laser and a 635 nm red 
diode laser. A total of 50 000 events were collected in the lymphocyte gate using morphological 
parameters (forward- and side-scatter). Data were processed using CellQuest Pro Software (Becton-
Dickinson) and analyzed using Kaluza® Analysis Software v.1.2 (Beckman Coulter, Inc.). The 
percentage of CD45RA+ and CD31+ cells was calculated within the CD3+CD4+ or CD3+CD8+ gate. 
CD45RA+ cells were defined as naïve and CD45RA+CD31+ expression was defined as RTE  
(Kimming, 2002). 
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1.2.5 TREC quantification  
Thymic output in PBMC was studied by measuring TREC levels by real-time polymerase chain 
reaction (PCR), exactly as described previously (Ometto, 2002; De Rossi, 2002). TREC levels were 
expressed as the number of TREC copies per 105 PBMC (De Rossi, 2002; Anselmi, 2007).  
 
1.2.6 Telomere length measurement 
Telomere length in PBMC was determined by real-time PCR exactly as described elsewhere 
(Rampazzo, 2010; Rampazzo, 2012) and values were expressed as the telomere to single copy gene 
(T/S) ratio (Rampazzo, 2010).  In a set of experiments, telomere length was measured in CD8+ cell 
subsets. CD8+ T cells were isolated from PBMC using magnetic beads coated with mAb against 
human CD8 (CD8 MultiSort Kit, Miltenyi, Bergisch Gladbach, Germany). Then, using magnetic 
beads coated with CD45RO (CD45RO MicroBeads, Miltenyi), the CD8+ cells were separated into 
CD8+CD45RO+ (memory cell subset) and CD8+CD45RO- (naïve cell subset).  
 
1.2.7 Telomerase activity quantification 
Telomerase activity was quantified as explained elsewhere (Rampazzo, 2012). Briefly, one million 
cells were lysed in 20µL of CHAPS buffer and incubated at 4°C for 30 min. The lysate was then 
centrifuged at 12000g for 30 min at 4°C, and the supernatant was collected as reported previously 
(Trentin, 1999). Telomerase activity was assessed with a real-time PCR method, using 250 ng of 
cellular protein extract for each sample, exactly as described in (Rampazzo, 2012). Telomerase 
activity was expressed in relative units (RU).  
 
1.2.8 Statistical analysis 
Given the exploratory nature of the present study, a target sample size of 60 patients (30 patients 
per group) was calculated according to Browe (Browe, 1995). The enrolment target was increased 
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to 90 to ensure an adequate sample size should some of the blood samples be excluded due to 
laboratory-related issues. 
Differences in geriatric parameters between cancer patients and controls were examined using the 
Mann-Whitney U test for non-parametric data and Pearson’s χ2 test with odds ratios (OR) and 95% 
confidence intervals (CI) for nominal data (CGA, MPI, ADL,  IADL).  
The Mann-Whitney U test was also used to compare subsets of lymphocytes, TREC levels and  
telomerase activity in cancer patients and controls. Correlations between age and TREC levels in 
both groups was analyzed with Pearson’s test.  Student’s t-test was used to compare the telomere 
lengths detected in PBMC from cancer patients and controls, then the assumptions of normality and  
homogeneity were verified. The relationship between age and telomere length was assessed with  
Pearson's test in both groups. Spearman’s rank correlation was used to analyze the associations 
between geriatric parameters and TREC levels, telomere lengths or telomerase activity. 
All statistical analyses were performed using SPSS software, rel. 18 (SPSS Inc., Chicago, IL, USA). 
All p-values were two-tailed, and were considered significant when lower than 0.05. 
 
1.3 RESULTS 
1.3.1 Characteristics of the study population  
Ninety-one patients, 52 with cancer (26 breast and 26 colorectal cancer) and 39 controls, were 
enrolled in the study. Their demographic and clinical characteristics are listed in Table 1A. There 
were more women in the control group (82.1%) than among the cancer patients (63.5%); the latter 
had better Karnofsky performance status than controls. As established by the study protocol, before 
enrollment, cancer patients underwent a thorough radiological assessment to rule out metastases. 
According to the TNM staging system, 16 patients (30.8%) had stage I, 33 (63.5%) stage II, and 3 
(5.7%) stage III disease. Thirty- one patients were prescribed the same adjuvant therapy as for 
younger adults, according to good clinical practice, 18 patients received an adapted treatment, due 
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to problems detected at the CGA, and 3 were given no adjuvant therapy, due to frailty detected at 
the CGA and were only followed up. 
 
1.3.2 Comprehensive geriatric assessment 
All cancer patients and controls routinely underwent the full CGA (Table 1B). Concerning their 
social condition, only one cancer patient (1.9%) lived in a nursing home due to dependence in at 
least one ADL; all the others lived at home, 42 (80.8%) with their family, and 9 (17.3%) alone. All 
controls lived at home, 25 (64.1%) with their family, and 14 (35.9%) alone. Cancer patients and 
controls all benefited from the assistance of a caregiver for a median time of 24 hours a day (range 
2-24 for cancer patients, 3-24 for controls).  
When the CGA findings were interpreted as reported in (Balducci, 2003), 17.3% of the cancer 
patients and 43.6% of the controls were classified as frail,  (OR=0.29, 95% CI 0.10-0.82; p=0.020). 
The proportion of vulnerable patients in the cancer (36.5%) and control (23.1%) groups did not 
differ significantly (OR=1.14, 95% CI 0.40-3.24, p=0.801) (Table 1B). The distribution of the MPI 
scores, grouped as low, moderate and severe (Pilotto, 2008), showed that 3 cancer patients (5.8%) 
and 9 controls (23.1%) had a moderate MPI (OR=0.20, 95% CI 0.05-0.79; p=0.022). The other 49 
cancer patients  (94.2%) and 29 controls (74.4%) had a low MPI, while only one control patient had 
a severe MPI score. When MPI was calculated as a continuous variable, the median score was 
significantly lower for cancer patients (0.19, range 0-0.44) than for controls (0.25, range 0.06-0.69), 
p=0.001 (Table 1B).                                          
As for ADL and IADL, the cancer patients tended to have preserved a greater physical autonomy 
than the controls, though the difference was not statistically significant. The cancer patients’  OR 
for independence in ADL and IADL was 2.44 (95% CI 0.88-6.74; p=0.790) and 0.11 (95% CI 0.81-
4.57; p=0.133), respectively. The controls had a better cognitive status, in both the MMSE and 
SPMSQ, but their burden of their associated diseases (as shown by the comorbidity and severity 
indexes calculated with the CIRS) was higher, and so was their use of drugs for these comorbidities. 
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Finally, the two groups were fully comparable in terms of their nutritional and humoral status  
(Table 1B).  
 
1.3.3 Standard hematological, biochemical parameters and CMV status 
The hematological parameters of cancer patients and controls differed only in their platelet count 
(Table 1C). Controls had significantly lower levels of nutritional markers, such as total plasma 
proteins, triglycerides, and LDL-cholesterol; CRP and IL-6 were significantly higher in controls 
than in cancer patients (Table 1C). The overall prevalence of CMV-IgG seropositive individuals 
was 96.7%. Antibodies against CMV were found in 49 (94.2%) of cancer patients and 39 (100%) of 
controls. No statistical difference was found between CMV antibody titers between the groups (p = 
0.498) (Table 1C). 
 
1.3.4. Immune senescence markers 
Cancer patients and controls had comparable percentages of total CD4+ lymphocytes, naïve CD4+ 
CD45RA+ CD27+ and RTE CD4+CD45RA+CD31+ cells (Table 1D). By contrast, the median 
(interquartile) percentages of naïve CD8+ CD45RA+ CD27+ and RTE CD8+CD45RA+CD31+ 
cells were significantly lower in cancer patients than in controls (16.7% [9.3–25.2] versus 24.6% 
[14.7–33.5]; p = 0.003) and (34.2% [24.7–46.4] versus 44.9% [36.0–50.7]; p = 0.004), respectively 
(Table 1D). Notably, the lower percentage of CD8+ naïve cells in cancer patients was compensated 
by a higher expansion of CD8+ memory cells; thus, cancer patients and controls did not differ in 
terms of their percentages of total CD8+ cells (Table 1D). In particular, among the CD8+ cell 
subsets, the CD45RA−CD27− (effector memory) cells were found to be significantly higher in 
cancer patients than in controls (21.7% [12.7–31.7] versus 16.3% [10.4–25.0]; p = 0.042). The 
imbalance in favor of the CD8 memory cell subset in cancer patients was evident even when the 
absolute cell count was considered (not shown). For a few subjects with available frozen samples 
(11 cancer patients and 8 controls), markers of immune senescence (CD28− CD57+ ) were 
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investigated. Cancer patients and controls exhibited similar percentages of CD4+CD28−CD57+, but 
CD8+ cells with senescent phenotype tended to be higher in the former (p = 0.082) (Table 1E). 
TREC levels in PBMC were significantly higher in controls than in cancer patients (25.0 [14.0–
56.0] versus 16.0 [7.7–31.5] TREC copies/105 PBMC; p=0.031) (Table 1D). TREC levels 
decreased significantly with increasing age in cancer patients (r = −0.478; p b 0.001), but did not 
correlate with age in controls (r = 0.071; p = 0.677) (Fig. 1A). 
The mean telomere length in PBMC was significantly lower in cancer patients than in controls; the 
former had a mean (±standard deviation (SD)) telomere length of 1.09 ± 0.31 T/S versus 1.22 ± 
0.30 T/S in controls, p=0.046 (Table 1D). Telomere length correlated inversely with age in controls 
(r = −0.354, p = 0.031), but not in cancer patients (r = −0.011, p = 0.938) (Fig. 1B). Telomerase 
activity was significantly higher in cancer patients, being detected in 38/52 patients (73.1%; median 
value 14.6 RU) and 20/38 controls (52.6%; median value 1.4 RU); p = 0.003. Telomerase activity 
was not influenced by age in either group. 
TREC was defined as high or low, and telomere length as long or short according to their values 
above and below the median, respectively. Subjects with TREC low/telomere short profile were at 
higher risk of cancer than subjects with only low TREC or short telomere (Table 1E). 
 
1.3.5. Relationship between TREC levels, telomere length and geriatric characteristics 
In the control group, CIRS-SI was the only tool which revealed a significant positive association 
with TREC level (r = 0.45, p = 0.01) and telomere length (r = 0.35, p = 0.03), whereas it had a 
significant nega- tive correlation with the number of drugs taken for concomitant diseases (r = 
−0.39, p = 0.02) (Table 1F). No relationship emerged between telomere length, thymic output and 
geriatric features. 
of cancer patients (Table 1F). Neither a classification of unfitness at CGA (not shown) nor the MPI 
score (Table 1F) correlated significantly with thymic output or telomere length in either group. 
Among the controls, TREC levels correlated positively with IL-6 (r = 0.34, p = 0.04) and negatively 
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with total plasma protein levels (r = −0.38, p = 0.02). Neither of these correlations emerged in the 
cancer patients (data not shown). 
 
1.4 DISCUSSION 
This is the first study aiming to shed light on two essential aspects of the ageing process (thymic 
output and telomere length in peripheral blood cells) in elderly cancer patients. These markers were 
studied in a sample of breast or colorectal cancer patients aged ≥70 years, as compared with a group 
of age-matched patients with no personal history of cancer. We found that our 70- to 92-year-old 
old cancer patients had significantly lower TREC levels in peripheral blood cells, a lower 
percentage of naïve and RTE CD8+ T lymphocytes, and a more expanded CD8+ memory cell subset 
than controls. Our results are partially consistent with those of a small trial in which head and neck 
cancer patients (most of them under 70 years old) revealed lower TREC levels than controls (Kuss, 
2005). The expansion of memory CD8+ cells is also consistent with the findings of another two 
recent studies conducted in breast cancer patients (Hueman, 2007; Poschke, 2012). The shift from 
naïve T cells to memory cells was probably due to a greater stimulation driven by tumor antigens. 
Since CD8+ T cells are the key components of tumor immune surveillance, the tumor-induced 
dysfunction may be more evident in the CD8 cell subset than in the CD4 cell compartment 
(Klebanoff, 2006; Williams, 2007). 
 
Our findings confirm the observations of a few other authors that thymic activity does not stop 
completely beyond 70 years of age (Ye, 2002, Nasi, 2006; Mitchell, 2010). 
Notably, while TREC levels in cancer patients dropped significantly with increasing age, in controls 
they remained relatively constant. It may be that thymic output compensates for the loss of 
peripheral blood lymphocytes in elderly patients, but this homeostatic phenomenon seems to 
disappear in cancer patients. The shortage of larger studies on TRECs in people over 70 makes it 
difficult to say more on this issue. 
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In our study sample, the control group included a higher proportion of frail patients (according to 
the CGA), and had higher average MPI scores, and more chronic diseases and comorbidities than 
the cancer patients. Systemic inflammation and loss of peripheral blood cells may stimulate thymic 
output, which has an important role in immunological homeostasis. In fact, TREC levels correlated 
significantly with CIRS-CI in the control group, but not in the cancer patients. The imbalance 
between the two groups in terms of their geriatric conditions reinforces the magnitude of the 
significant difference observed in the cancer patients’ and controls’ TREC levels. 
 
The hypothesis that immune activation can explain the finding of immune senescence in controls is 
supported by the CRP and (even more relevant) IL-6 levels, that were both found significantly 
higher in controls than in cancer patients. The role of IL-6, a circulating proinflammatory cytokine, 
as a marker of low-grade inflammation has been confirmed in various studies (Ferrucci, 1999; 
Ershler, 2000). Consistently with our data, its overproduction has been associated with a number of 
age-related illnesses and functional disabilities (Heikkila, 2008). In a few small studies, IL-6 levels 
were higher in cancer patients than in healthy controls (Vasto, 2006), whereas our opposite  
findings confirm the conclusions reached by other authors (Ershler, 2000; Heikkila, 2008) that large 
prospective studies are needed to clarify the role of IL-6, especially in elderly people.  
While the hypothesis of immune homeostasis might justify a higher thymic output in controls, the 
age-related lower TREC levels seen in cancer patients may point to a pre-existing condition 
favoring immune escape and the onset of malignant disease. Be that as it may, the present 
exploratory study showed that cancer patients suffer from a more serious immune senescence than 
controls, but is unable to establish whether this is a consequence of cancer or related to a pre-
existing immune impairment substrate facilitating the onset of cancer.  
 
As concerns telomere length, a broad array of publications have explored the meaning of telomeres 
and telomerase activity in cancer patients, and there is plenty of data available on the relationship 
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between telomere length and aging-associated changes and chronic diseases (Wong, 2003; Aviv, 
2006; Baird, 2006). On the other hand, telomere and telomerase behavior in the peripheral blood 
cells of elderly cancer patients was a matter that had yet to be explored. Our study showed that 
cancer patients’ telomeres in PBMC are significantly shorter than those seen in controls. In addition, 
while control patients’ telomeres became shorter with age, as expected on the strength of previous 
studies (Blasco, 2005; Steenstrup, 2013; Der, 2013), no such relationship between age and telomere 
length was seen in our cancer patients. This difference cannot be explained by a lower telomerase 
activity in cancer patients because telomerase activity was detected in the peripheral blood cells of 
most cancer patients, but virtually absent in those of most controls. The fact that our controls scored 
worse for the severity and comorbidity indexes than our cancer patients strongly emphasizes the 
magnitude of the difference in the two groups’ telomere length. 
 
While several studies have found shorter telomeres in tumor cells than in surrounding non-cancer 
cells (Bisoffi, 2006;  Rampazzo, 2010), the intriguing finding of shorter telomeres in peripheral 
blood cells cannot be justified by the presence of cancer cells in the peripheral blood. Our cancer 
patients had radically-resected, early breast or colorectal cancer and had undergone a thorough 
radiological assessment to exclude either persistent local disease or distant metastases. As reported 
elsewhere (Franken, 2012; Shimada, 2012), the number of epithelial cells detectable in the 
peripheral blood in patients with early breast or colorectal cancer is so small that it cannot influence 
the telomere length or telomerase activity. We surmised that our control patients’ longer telomeres 
related to this group’s higher proportion of naïve-CD8+ cells. To explore this issue, we separately 
estimated telomere length in CD8 naïve and CD8 memory cells from 3 cancer patients: the two 
subsets had a similar telomere length, suggesting that the shorter telomeres cannot be explained by 
an excessive replication/expansion of the memory cell subset (not shown). We therefore suggest 
that telomere length in peripheral blood reflects the more advanced  biological aging of the immune 
system in cancer patients than in controls, a pre-existing condition that facilitated the  onset of 
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cancer in the former. This hypothesis is in agreement with the findings of a case-control study 
involving 215 female lung cancer cases and 215 female controls. Authors reported a significant 
dose-response relationship between telomere length and risk of lung cancer  (Lan, 2013). Also the 
results of a large trial involving more than 100.000 breast and ovarian cancer patients are  consistent 
with the hypothesis that shorter telomeres predispose to increased cancer risk (Bojesen, 2013). 
 
 Neither thymic output markers nor telomere length correlated with the results of the CGA or MPI 
scores in our sample. There are no data in the literature on elderly cancer patients with which to 
compare our findings, while two other studies have explored the association between telomere 
length and frailty in elderly non-cancer patients: neither study found frailty indexes associated with 
telomere length (Collerton, 2012; Woo, 2008); and findings in our control group are consistent with 
their results. So, although telomere length is a marker of biological aging, their relationship cannot 
be extrapolated to the functional level represented by the geriatric assessment of frailty, largely 
contributed by several factors. 
 
In conclusion, this exploratory study is the first to find that elderly cancer patients had significantly 
shorter telomeres in their peripheral blood cells than  age-matched non-cancer patients. This result 
suggests the unpublished hypothesis – which would need to be tested in a larger study - that elderly 
people with shorter telomeres are at higher risk of developing cancer. Our elderly cancer patients 
also seemed to suffer from a more severe decline in thymic output and had a lower proportion of 
naïve CD8+ cells than age-matched controls. It is noteworthy that the cancer patients’ thymic output 
decreased significantly with increasing age, while telomere length in the peripheral blood cells was 
unassociated with age. Finally, this preliminary study also confirms that there is no relationship 
between the geriatric phenotypes investigated by the CGA and these molecular markers of aging. 
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Table 1A. Demographic and clinical characteristics of cancer patients and controls 
  
  
All  
patients,  
No. (%) 
Cancer 
 patients,  
No. (%) 
Controls,  
No. (%) 
Age (yrs)    
 No. Median, range 
91 (100) 
81, 70-92 
52 (57.2) 
81, 72-92 
39 (42.8) 
80, 70-91 
Gender    
 Male Female 
26 (28.6) 
65 (71.4) 
19 (36.5) 
33 (63.5) 
7 (17.9) 
32 (82.1) 
Performance status (ECOG)    
 0-1 ≥2 
83 (91.2) 
8 (8.8) 
51 (98.1) 
1 (1.9) 
32 (82.1) 
7 (17.9) 
Social Condition 
                    Home 
                    Nursing home 
  
90 (98.9) 
1 (1.1) 
 
51 (98.1) 
1 (1.9) 
 
39 (100) 
0 (0.0) 
Type of Assistance 
                    Alone 
                    Family 
                    Others 
 
 
23 (25.3) 
59 (64.8) 
9 (9.9) 
 
9 (17.3) 
38 (73.1) 
5 (9.6) 
 
14 (35.9) 
21 (53.8) 
4 (10.3) 
Caregiver Assistance (hours/day) 
                    Median time, range  
 
24, 2-24 
 
24, 2-24 
 
24, 3-24 
Tumor Stage (TNM) 
                    I 
                    II 
                    III 
 
 
- 
- 
- 
 
16 (30.8) 
33 (63.5) 
3 (5.7) 
 
- 
- 
- 
Modality of Diagnosis 
                         Symptoms/Self examination 
                   Screening 
                   Incidental diagnosis 
 
 
- 
- 
- 
 
40 (76.9) 
9 (17.3) 
3 (5.8) 
 
- 
- 
- 
Therapeutical Choice 
                  Adjuvant therapy as for 
                  younger adults               
                  Adapted tratment 
                  No adjuvant therapy 
 
 
 
- 
- 
- 
 
 
31 (59.6) 
18 (34.6) 
3 (5.8) 
 
 
- 
- 
- 
Agreement to Proposed Therapy 
                  Ready 
                  Patient refusal 
 
 
- 
- 
 
51 (98.1) 
1 (1.9) 
 
- 
- 
Cause of Admission to hospital/ 
Outpatient Services 
                  Cardiovascular disease 
                  Peripheral deep venous 
                  thrombosis 
                  Gastrointestinal inflammatory 
                  disorders or bleeding 
                  Screening of osteoporosis 
                  with no active comorbidity 
 
 
 
- 
 
- 
 
- 
 
- 
 
 
- 
 
- 
 
- 
 
- 
 
 
18 (46.2) 
 
4 (10.2) 
 
5 (12.8) 
 
12 (30.8) 
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Table 1B. Scores of geriatric tools in cancer patients and controls 
 
 
Geriatric Tool All patients Cancer patients Controls OR (95% CI) p-value 
CGA, No. (%) 
      Fit 
      Vulnerable 
      Frail 
MPI, No (%) 
      Low 
      Moderate 
      Severe 
MPI 
      Median, range 
Dependencies in ADL, No (%) 
      No  
      ≥1  
Dependencies in IADL, No (%) 
     No 
      ≥1  
MMSE 
     Median [IQR] 
SPMSQ 
     Median [IQR] 
CIRS-CI 
    Median [IQR] 
CIRS-SI 
    Median [IQR] 
GDS 
    Median [IQR] 
BMI 
    Median [IQR] 
Drugs for concomitant diseases 
   Median [IQR] 
 
37 (40.7) 
28 (30.7) 
26 (28.6) 
 
78 (85.7) 
12 (13.2) 
1 (1.1) 
 
0.25, 0.00-0.69 
 
71 (78.0) 
20 (22.0) 
 
57 (62.6) 
34 (37.4) 
 
27.1 [24.4-28.4] 
 
1.0 [0.0-2.0] 
 
3.0 [1.0-4.0] 
 
1.5 [1.3-1.6] 
 
3.0 [1.0-6.0] 
 
25.7 [24.0-27.4] 
 
5 [3-6] 
 
24 (46.2) 
19 (36.5) 
9 (17.3) 
 
49 (94.2) 
3 (5.8) 
0 (0.0) 
 
0.19, 0.00-0.44 
 
44 (84.6) 
8 (15.4) 
 
36 (69.2) 
16 (30.8) 
 
26.2 [24.4-27.3] 
 
1.0 [0.0-2.0] 
 
2.0 [1.0-3.0] 
 
1.4 [1.2-1.5] 
 
3.0 [1.2-6.0] 
 
25.8 [24.2-26.9] 
 
4 [2-5] 
 
13 (33.3) 
9 (23.1) 
17 (43.6) 
 
29 (74.3) 
9 (23.1) 
1 (2.6) 
 
0.25, 0.06-0.69 
 
27 (69.2) 
12 (30.8) 
 
21 (53.8) 
18 (46.2) 
 
28.3 [26.4-29.3] 
 
0.0 [0.0-2.0] 
 
3.0 [2.0-4.0] 
 
1.6 [1.4-1.8] 
 
3.0 [1.0-6.0] 
 
25.0 [23.0-28.6] 
 
5 [4-8] 
 
1 
1.14 (0.40-3.24) 
0.29 (0.10-0.82) 
 
1 
0.20 (0.05-0.79) 
<0.01 
 
- 
 
1 
0.41 (0.15-1.14) 
 
1 
0.52 (0.22-1.23) 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
 
0.801 a 
0.020  a 
 
 
0.022  a 
ns  a 
 
0.001 a 
 
 
0.790 a 
 
 
0.133 a 
 
0.001 b 
 
0.013 b 
 
0.032 b 
 
<0.001 b 
 
0.888  b 
 
0.911b 
 
0.003 b 
 
                  a Pearson's χ2 or Fisher test       
                  b Mann-Whitney U test 
  
Table 1C. Standard blood parameters: comparison between cancer patients and controls 
 
Parameter All patients 
Median [IQR] 
Cancer patients 
Median [IQR] 
Controls 
Median [IQR] 
p-value a 
Leucocytes (x109/l) 
 
Lymphocytes (x109/l) 
 
Neutrophils (x109/l) 
 
Hemoglobin (g/l) 
 
Platelets (x109/l) 
 
Total plasmatic proteins (g/l) 
 
Albumin (%) 
 
Gamma globulins (%) 
 
Triglycerides (mmol/l) 
 
Total cholesterol (mmol/l) 
 
LDL-cholesterol (mmol/l) 
 
HDL-cholesterol (mmol/l) 
 
Creatinine (umol/l) 
 
IgG (g/l) 
 
IgA (g/l) 
 
IgM (g/l) 
 
IL-6 (ng/l) 
 
CRP (mmol/l) 
 
 
 
6.6  [5.3-7.9] 
 
1.6 [1.3-1.9] 
 
3.8 [3.0-4.9] 
 
127.0 [114.0-140.0] 
 
236.0 [204.0-291.0] 
 
66.8 [63.5-71.1] 
 
57.0 [54.0-59.6] 
 
15.2 [13.2-17.3] 
 
1.1 [0.8-1.4] 
 
4.9 [3.9-5.8] 
 
2.8 [2.0-3.7] 
 
1.4 [1.1-1.9] 
 
76.0 [68.0-93.0] 
 
10.5 [8.5-12.2] 
 
2.3 [1.8-2.9] 
 
0.9 [0.5-1.3] 
 
3.0 [1.9-5.3] 
 
3.5 [2.9-6.6] 
 
 
 
6.7 [5.5-7.9] 
 
1.7 [1.3-1.9] 
 
3.9 [3.2-4.9] 
 
128.0 [111.0-142.0] 
 
253.5 [212.5-317.0] 
 
68.4 [66.1-74.3] 
 
57.9 [54.7-60.6] 
 
14.9 [13.3-17.1] 
 
1.2 [0.8-1.7] 
 
5.1 [4.3-5.7] 
 
3.3 [2.7-3.8] 
 
1.4 [1.1-1.7] 
 
77.5 [68.2-95.0] 
 
10.3 [8.9-11.6] 
 
2.6 [1.8-3.4] 
 
0.8 [0.5-1.3] 
 
2.6 [1.9-4.3] 
 
3.5 [2.9-5.5] 
 
 
 
5.9 [5.0-7.5] 
 
1.5 [1.2-1.9] 
 
3.6 [2.7-4.9] 
 
126.0 [116.0-138.0] 
 
225.0 [183.0-260.0] 
 
64.0 [60.7-68.7] 
 
55.9 [53.9-58.2] 
 
15.8 [13.0-18.0] 
 
0.9 [0.7-1.2] 
 
4.5 [3.7-5.8] 
 
2.4 [1.7-3.6] 
 
1.6 [1.1-1.9] 
 
75.0 [68.0-93.0] 
 
11.0 [7.7-12.6] 
 
2.2 [1.6-2.7] 
 
0. 9 [0.5-1.4] 
 
3.7 [2.1-6.3] 
 
3.5 [3.4-10.8] 
 
 
 
0.110 
 
0.165 
 
0.141 
 
0.665 
 
0.011 
 
<0.001 
 
0.530 
 
0.549 
 
0.009 
 
0.229 
 
0.006 
 
0.194 
 
0.642 
 
0.934 
 
0.104 
 
0.853 
 
0.033 
 
0.044 
 
 
 
  
CMV b 
 
    n positive/n tested (%)   
  
    IgG  (UI/ml) 
 
 
88/91 (96.7%) 
 
15000 [8200-21000] 
 
 
49/52 (94.2%) 
 
15000 [8125-19750] 
 
 
 
39/39 (100%) 
 
15000 [9300-24000] 
 
 
0.498 
                      
a Mann-Whitney U test 
b CMV serology: Serum CMV antibody (IgG) titers (Enzygnost® Anti-CMV/IgG) >230 were considered to be positive. 
  
Table 1D. Thymic output and telomere length in cancer patients and controls 
 
 
Parameter 
 
All patients 
Median [IQR] 
Cancer patients 
Median [IQR] 
Controls 
Median [IQR] 
 
p-value 
 
% CD3+   54.3 [40.8-65.2] 53.6 [37.8-65.5] 56.3 [41.8-65.2] 0.560 a 
     
% CD4+  35.5 [25.6-49.1] 35.0 [21.1-46.7] 35.6 [26.6-51.8] 0.389 a 
                                 
% CD8+   15.7 [10.1-22.4] 15.4 [9.7-22.6] 16.4 [10.5-22.8] 0.717 a 
     
% naïve, CD4+CD45RA+  
               
37.4 [27.2-51.3] 36.0 [24.2-50.6] 40.0 [30.2-53.0] 0.137 a 
    
% naïve, CD8+CD45RA+   54.1 [45.0-65.2] 50.2 [39.8-62.9] 55.7 [52.6-65.8] 0.016 a 
                   
% RTE, CD4+CD45RA+CD31+  
 
21.3 [14.2-33.4] 
 
20.3 [10.4-32.0] 
 
23.3 [16.8-33.5] 
 
0.176 a 
 
% RTE, CD8+CD45RA+CD31+  
 
37.6 [29.1-48.9] 
 
34.2 [24.7-46.4] 
 
44.9 [36.0-50.7] 
 
0.004 a 
 
TREC copy number/105 PBMC 
 
19.0 [10.1-37.0] 
 
16.0 [7.7-31.5] 
 
25.0  [14.0-56.0] 
 
0.031 a 
 
Telomere length (T/S ratio)c 
 
1.15 ± 0.30 1.09 ± 0.31 1.22 ± 0.30 0.046 b 
Telomerase activity 
              No. positive/ No. tested 
              Relative Units 
 
58/90 
5.6 [0.0-26.0] 
 
38/52 
14.6 [0.0-36.8] 
 
20/38 
1.4 [0.0-6.4] 
 
 
0.003 a 
a Mann-Whitney U test 
b Student t-test 
c Data are expressed as mean ± Standard Deviation 
 
 
 
 
                            
                          Table 1E.   TREC and telomere  profile on cancer patients  and controls 
 
 Cancer Patients 
No. (%) 
Controls 
No. (%) OR (95% CI) p-value 
TREC levels a 
TREC high 
TREC low 
 
20 (40.0%) 
30 (60.0%) 
 
23 (62.2%) 
14 (37.8%) 
 
1 
2.46 (1.03-5.90) 
 
 
0.043 
 
Telomere length b 
T/S long 
T/S short 
 
21 (40.4%) 
31 (59.6%) 
 
23 (62.2%) 
14 (37.8%) 
 
1 
2.43 (1.02-5.76) 
 
 
0.045 
 
TREC levels & Telomere 
length  
Others c 
TREC low & T/S short 
 
 
 
31 (62.0%) 
19 (38.0%) 
 
 
30 (85.7%) 
  5 (14.3%) 
 
 
 
1 
3.68 (1.22-11.11) 
 
 
 
0.021 
 
                            a TREC low: TREC ≤ median, TREC high: TREC > median 
                            b T/S short: T/S ≤ median, T/S long: T/S > median (the median value is coincident with the mean value) 
                            c Others: TREC high & T/S long, TREC low & T/S long and TREC high & T/S short 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
Table 1F. Relationship between markers of immune senescence and geriatric scores in cancer patients and controls 
 
 TREC level  Telomere length  Telomerase activity 
 
All patients Cancer patients Controls 
 All 
patients 
Cancer 
patients Controls 
 
All patients Cancer patients Controls 
MPI -0.03, 0.77 -0.04, 0.78 -0.24, 0.16  -0.04, 0.74 0.01, 0.95 -0.26, 0.13  -0.03, 0.81 0.16, 0.25 0.00, 0.98 
MMSE -0.1, 0.35 -0.28, 0.05* -0.14, 0.42  0.06, 0.61 0.15, 0.28 -0.31, 0.06  -0.14, 0.19 -0.17, 0.22 0.19, 0.25 
CIRS-CI -0.04, 0.71 0.04, 0.79 -0.31, 0.07  0.04, 0.70 0.05, 0.72 -0.05, 0.76  -0.12, 0.26 0.01, 0.94 -0.18, 0.27 
CIRS-SI 0.26, 0.02* -0.07, 0.61 0.45, 0.01**  0.16, 0.13 -0.11, 0.42 0.35, 0.03*  -0.06, 0.60 0.01, 0.95 0.18, 0.27 
GDS -0.03, 0.79 -0.19, 0.19 0.22, 0.18  -0.10, 0.34 -0.09, 0.54 -0.05, 0.75  -0.24, 0.02* -0.20, 0.15 -0.26, 0.12 
BMI -0.03, 0.79 0.01, 0.96 -0.10, 0.57  0.02, 0.83 0.14, 0.31 -0.11, 0.53  0.27, 0.01** 0.29, 0.04* 0.14, 0.39 
Concomitant 
drugs -0.01, 0.91 0.11, 0.43 -0.39, 0.02
*  -0.13, 0.24 -0.18, 0.21 -0.24,0.15  -0.02, 0.89 0.13, 0.36 0.08, 0.65 
   Data are expressed as Spearman's rho coefficient, p-value. 
      *   Correlation is significant at the level 0.05 (two-tailed) 
      ** Correlation is significant at the level 0.01 (two-tailed) 
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Fig. 1A. Correlation between age and (A) TREC levels and (B) telomere lengths in cancer patients 
and controls. Panel (A): TREC levels decline with age in peripheral blood cells of cancer patients (r 
= −0.478, p b 0.001), but not in controls (r = 0.071, p = 0.677). Panel (B): telomere lengths decrease 
with age in peripheral blood cells of controls (r = −0.354, p = 0.031), but not in cancer patients (r = 
−0.011, p = 0.938). 
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CHAPTER 2 
The Mortality Risk 
 
DOES THE MULTIDIMENSIONAL PROGNOSTIC INDEX (MPI), BASED ON A 
COMPREHENSIVE GERIATRIC ASSESSMENT (CGA), PREDICT MORTALITY IN CANCER 
PATIENTS? RESULTS OF A PROSPECTIVE OBSERVATIONAL TRIAL 
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2.1 BACKGROUND AND AIMS 
A large proportion of cancer patients are at least 70 yrs old (Siegel, 2012). In recent decades, strong 
evidence has emerged to indicate that age alone is not an absolute contraindication for cancer 
treatments. Instead of chronological age, a patient’s biological age - estimated by means of a 
thorough geriatric assessment - should drive any therapeutic decisions (Balducci, 2003).  
In fact, the complexity of geriatric and oncological parameters and their interactions are such that 
proposing anticancer treatment for these elderly patients means entering a controversial field. On 
the one hand, oncologists must deal with the risk of cancer-related morbidity and mortality, while 
on the other they have to consider the patient’s life expectancy irrespective of their neoplasm 
(Extermann, 2005; Surbone, 2007).  
Given the serious difficulty of managing older cancer patients, for some years now numerous 
oncologists (Extermann, 2004; Basso, 2007; Marenco, 2008;) have been focusing on an approach to 
cancer patients based on a Comprehensive Geriatric Assessment (CGA), because the importance of 
evaluating the geriatric aspects as well as those strictly related to the neoplastic disease is becoming 
increasingly clear. 
The CGA was first introduced in geriatric clinics to identify potential causes of frailty because  frail 
patients are often heterogeneous in their clinical presentation and complicated to care for 
(Extermann, 2003; balducci, 2000). The CGA is now widely used in everyday clinical geriatric 
practice to deal with patients who have  concomitant diseases and different functional conditions 
(Ferrucci, 2001). This tool is used not only for the baseline assessment and diagnosis, but also for 
serial, prospective patient management. Since one of its main features is that it is interdisciplinary, 
the CGA is a useful tool for investigating the frail (Rubenstein, 2004; frees, 2012). 
In the context of geriatric oncology, the CGA has proved essential for distinguishing patients who 
are fit and deserve the same active oncological treatment as younger adults from vulnerable patients 
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eligible for an adapted treatment with lower doses of drugs and strict monitoring, and frail patients 
too sick to receive treatments other than the best supportive care (Balducci, 2007).  
Since the pioneering times of geriatric oncology in the 1980s, the concept of CGA has progressed 
and the Multidimensional Prognostic Index (MPI), based on a geriatric assessment (Pilotto, 2005; 
Pilotto, 2008), has been developed. The MPI assesses 8 domains derived from geriatric scales 
widely used in clinical practice, relating to functional, cognitive and nutritional conditions, 
comorbidities and pressure sore risk. It also considers clinical issues such as medication, and social 
aspects too. The MPI has been validated in two independent cohorts of elderly hospitalized patients 
(Pilotto, 2005): a worse MPI was positively associated with a higher risk of mortality. The 
prognostic value of the MPI has been confirmed in cohorts of hospitalized patients with acute or re-
emerging chronic diseases, such as pneumonia, dementia, gastrointestinal bleeding, heart failure, 
and metabolic syndrome (Pilotto, 1995; Pilotto, 2007; Pilotto, 2009).  
Yourman et al (Yourman, 2012) recently conducted a systematic assessment of the qualities and 
limitations of various disease-specific prognostic indices for all-cause mortality in older adults. 
Among the indices validated for hospitalized patients, the MPI was judged to be well calibrated and 
demonstrated a good discrimination in the validation cohort. The MPI has never been validated for 
the purposes of predicting mortality in cancer patients, however, where the need for a prognostic 
index that does not only consider the patient’s oncological features is strongly felt (Monfardini, 
2012).  
The main aim of the present study was to ascertain the prognostic value of the MPI at 6 and 12 
months in geriatric cancer patients. A second aim was to investigate whether other geriatric issues 
not considered in the MPI, but extremely relevant in the traditional CGA, could strengthen the 
prognostic value of the MPI when applied to cancer patients.  
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2.2 PATIENTS  AND METHODS  
 
2.2.1 Study population 
Patients aged 70 yrs and older admitted between 17 April 2008 and 19 April 2011 to the Geriatric 
Clinic, Geriatric Surgery Clinic and Medical Oncology Unit at Padua Hospital with a recently-
diagnosed cancer were screened for eligibility.  
Our inclusion criteria were as follows: 1) histologically confirmed diagnosis of inoperable, locally 
advanced or metastatic solid cancer; 2) ability to provide informed consent or availability of a 
legally-allowable representative; 3) feasibility of obtaining a CGA at enrollment; 4) willingness of 
patients and their caregivers to answer questionnaires. Patients presenting with a cognitive 
impairment severe enough to hamper communication with physicians were excluded by the study. 
The following details were collected at the baseline: date of birth, gender, formal education, weight, 
height, body mass index (BMI), body surface area (BSA), calculated as (W 0.425 x H 0.725) x 
0.007184) (26), clinical history, and past and present medication, current pathologies, sites of 
primary cancer, any metastases, and cancer treatments received.  
All patients submitted to a standard CGA at the time of their first oncological visit as reported 
below. Living status was assessed by directly contacting the participants (or their caregivers), or 
consulting the Registry Offices of the cities where the patients resided; dates of death were obtained 
from death certificates.   
The present study was approved by our Institutional Ethics Committee  and conducted according to 
the Declaration of Helsinki and the guidelines of Good Clinical Practice. Written informed consent 
was obtained from patients or the relatives of the demented or critically ill prior to their enrollment 
in the study.  
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2.2.2 The Comprehensive Geriatric Assessment (CGA) 
The CGA was administered by a multidisciplinary team that included a medical oncologist, 
geriatricians and psychologists, at the time of first admission to the referring units due to a 
diagnosis of cancer. 
Functional status was evaluated using the Activities of Daily Living (ADL; Katz, 1970) and 
Instrumental Activities of Daily Living (IADL; Lawton, 1969) scales. Cognitive Status was 
assessed with the Short Portable Mental Status Questionnaire (SPMSQ; Pfeiffer, 1975) and Mini 
Mental Status Examination (MMSE; Pfeiffer, 1975; Folstein, 1975).  
Comorbidities and their severity were examined using the Cumulative Illness Rating Scale-
Comorbidity Index (CIRS-CI) and the Cumulative Illness Rating Scale-Severity Index (CIRS-SI) 
(Conwell, 1993). Nutritional Status was explored with the Mini Nutritional Assessment (MNA) 
(Guigoz, 1999). The risk of developing pressure sores was tested with the Exton Smith Scale (ESS) 
(Blitz, 1966). Medication taken was defined as the number of different drugs used by patients for 
concomitant diseases and disorders at the time of admission. Social aspects included household 
composition and home services, and institutionalization was also noted.  
In addition to the MPI, other geriatric aspects were considered, including: affective status, 
evaluated with the Geriatric Depression Scale (GDS; Yesavage, 1983); self-reported pain, assessed 
with the Visual Numeric Scale (VNS; Ritter, 2006); and the burden of care for caregivers, 
measured with the Caregiver Burden Inventory (CBI; Novak, 1989). 
 
2.2.3 The Multidimensional Prognostic Index (MPI) 
The MPI score was calculated for each patient from the results of the various tests (ADL, IADL, 
SPMSQ, CIRS-CI, MNA, ESS, number of drugs, and social conditions), as reported elsewhere by 
Pilotto et al (Pilotto, 2007; Pilotto, 2009; Pilotto, 2010). As in their original publications, three 
grades of severity risk were also considered to better stratify the study population (Table 2A), i.e. 
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low mortality risk (MPI ≤ 0.33), moderate risk (MPI between 0.34 and 0.66), and high risk (MPI > 
0.66). 
 
2.2.4 Statistical analysis  
The analyses were performed using SAS (9.2) statistical software from the SAS Institute, Cary 
(NC). 
The distribution of the demographic and clinical variables between the men and women, and across 
the MPI scores was summarized in the form of means and standard deviations (SD) or frequencies. 
Comparisons between groups and categorical variables were assessed with the chi-square or 
Fisher’s exact test (two-tailed). Differences between the means for groups were analyzed, if 
normally distributed, with the Generalized Linear Models (GLM) procedure, after testing for 
homoscedasticity with Levene’s test (and Welch’s test was performed when this assumption was 
not confirmed); if the differences were not normally distributed, non-parametric (Mann-Whitney U, 
Kruskal-Wallis) tests were used. 
The associations between the time to death at the 6- or 12-months follow-up and the MPI scores, 
individual MPI domains, and clinical characteristics was analyzed using a Cox’s proportional 
hazards regression model adjusted for age and gender. Hazard ratios (HR) and 95% confidence 
intervals (CI) were calculated to estimate the strength of the associations. Multivariate Cox’s 
regression analyses with a stepwise procedure (considering a threshold level of 0.15) were used to 
identify other possible mortality predictors (formal education, BSA, CIRS-SI, MMSE, GDS, VNS, 
CBI, site of primary tumor, metastases, cancer treatments), in addition to the MPI. Observation time 
was calculated as the time elapsing from admission to death or the end of the follow-up, whichever 
came first. The assumption of proportionality was assessed by analyzing the Schoenfeld residuals of 
the covariates introduced in the model. Age- and sex-adjusted survival curves were also derived 
from the Cox’s regression. 
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The discriminatory power of the mortality model at 6 and 12 months of  follow-up was assessed by 
calculating the area under the ROC curves for the MPI (considered as a continuous variable) using 
logistic regression models. 
A p value <0.05 was considered statistically significant.  
 
 
 2.3 RESULTS  
 
2.3.1 Characteristics of study population  
Of the 171 patients screened using our inclusion criteria, 11 patients were excluded because: they 
refused to take part in the study (3 patients); they were unable to complete the CGA (6 patients); or 
they could not sign the informed consent and had no legally-allowable representative (2 patients). 
The final study population thus included 160 patients, 88 females (55%) and 72 males (45%), with 
a mean age of 79.4 ± 5.7 years (range 69-93), and a mean formal education 6.4 ± 3.6 years (range 0-
19).  
Histological confirmation of the diagnosis of cancer was not available for 4 patients (2.5%) whose 
low performance status contraindicated any invasive diagnostic procedures. The diagnosis of cancer 
was judged highly likely in these patients, however, based on specific physical or radiological 
findings.   
The baseline characteristics of the study population by gender are shown in Table 2.B. There were 
significant gender-related differences in the sample’s weight, height, BSA, GDS, CIRS-SI, CIRS-
CI, site of primary tumor, endocrine therapy, and social conditions. The overall mortality rate was 
34.4% (55 patients) at 6 months and 46.9% (75 patients) at 12 months of follow-up, with no  
significant differences between males and females.  
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2.3.2 Distribution by MPI  
The main features of the study population by MPI score are shown in Table 2.C. Ninety-six patients 
(60%) had a low MPI, 48 (30%) a moderate MPI and 16 (10%) a severe MPI. The MPI scores were 
significantly associated with all the single MPI domains, age, weight, BMI, BSA, CIRS-SI, MMSE, 
GDS, VNS, CBI, and site of primary tumor. No significant associations emerged between MPI and 
formal education, gender, height, metastases and any oncological treatments. 
 
2.3.3 Prognostic value of the MPI  
Increasing mortality rates after 6 and 12 months of follow-up coincided with higher MPI scores (see 
Table 2.C). 
In the univariate Cox’s regression analyses, MPI adjusted for age and sex, most of its individual 
components (ADL, IADL, MNA, CIRS-CI, ESS), and also BSA, CIRS-SI, GDS, VNS, CBI, site of 
primary tumor, and presence of metastases, were significant predictors of mortality at 6 and 12 
months of follow-up (Table 2.D).  
The MPI-related hazard ratios were higher at 6 months of follow-up than at 12 months, a high MPI 
being associated with a HR of 8.094 (95% CI 3.749-17.475, p<0.0001) at 6 months as opposed to 
5.655 (95% CI 2.866-11.158, p<0.0001) at 12 months. When the MPI was considered as a 
continuous variable, any increase by 0.2 units (corresponding to the lower quartile) was associated 
with a 2.347-fold increase in the mortality risk (95% CI=1.838-2.997) at 6 months and a 2.051-fold 
increase (95% CI=1.662-2.531) at 12 months. Figure 2A shows the age- and sex-adjusted survival 
curves for the three subgroups with low, moderate and high MPI scores; patients with high MPI 
scores had a significantly higher mortality rate than patients with lower MPI scores (p<0.0001).  
Age- and sex-adjusted multivariate Cox’s regression analyses conducted to assess the potential 
mortality risk factors (with MPI as a continuous variable, formal education, BSA, CIRS-SI, MMSE, 
GDS, VNS, CBI, site of primary tumor, metastases, and oncological treatments) at the two time 
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points are presented in Table 2.E. MPI, CIRS-SI, BSA, GDS, MMSE, chemotherapy and a 
diagnosis of primary lung cancer were associated with mortality at 6 and 12 months. 
The discriminatory power of the MPI’s predictive performance was statistically significant (Table 
2.F). 
The age- and sex-adjusted area under the ROC curve for MPI score at 6 and 12 months of follow-up 
were 0.81 (95% CI, 0.74-0.88) and 0.78 (95% CI, 0.71-0.85), respectively. The prognostic 
performance of the MPI was also assessed in a regression model adjusted for age, sex and the other 
mortality predictors verified at the multivariate analysis. This last model seems better able to predict 
mortality both at 6 months (area under the ROC curve =0.94, 95% CI 0,869-0.959, p<0.0001) and 
12 months (area under the ROC curve =0.87, 95% CI 0,819-0.928, p<0.0001) of follow-up (Table 
2.F). 
 
2.4 DISCUSSION 
To our knowledge, this is the first prospective study to evaluate the prognostic value of the MPI in a 
cohort of ECP. According to the current practice guidelines of the major international societies of 
oncology, some form of geriatric assessment applied to ECP should be mandatory before any major 
treatment decisions are made (Surbone, 2007, Extermann, 2005) in order to estimate their life 
expectancy irrespective of their tumor and to explore their functional reserves and the risk of 
treatment complications. There is still no consensus on the best form of geriatric assessment in the 
oncological setting (Falci, 2011). One of the main drawbacks of applying a conventional CGA to 
oncological patients lies in its lack of standardization. A number of investigators have developed 
scoring systems, based in various ways on the CGA, to estimate short- and long-term mortality. 
Among the short-term mortality predictors, the MPI is probably the most appealing because it 
summarizes the information obtainable from most of the items in the CGA in a single score ranging 
from 0 to 1 (Pilotto, 2008).  
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This study showed that the MPI significantly predicted all-cause mortality at 6 and 12 months in a 
cohort of elderly patients with locally advanced or metastatic disease. At the multivariate Cox’s 
regression analysis, the MPI showed the highest hazard ratio, even compared with the patients’ 
oncological features.  
This finding is extremely important, in our opinion, because it confirms that the prognosis is not 
influenced by the oncological picture alone in elderly adults with advanced cancer, but also by the 
their geriatric features (most of which are included in the MPI).  
Given that solid cancers in an advanced stage are well known to carry an unfavorable prognosis, 
some might argue that this selection criterion dramatically impairs the utility of testing a prognostic 
index such as the MPI. Conversely, our results indicate that the presence of advanced cancer does 
not per se impair the prognostic value of the MPI.   
This finding is consistent with results reported by Basso et al, who recently evaluated the prognostic 
meaning of traditional CGA in more than 800 cancer patients: their status according to the CGA 
predicted a different survival for different groups in the cohort of patients as a whole, and 
significance was maintained for the differences between the subgroups of patients in the 
adjuvant/neoadjuvant setting and those with advanced disease (Basso, 2011). 
A number of conventional geriatric characteristics also retained their prognostic value in our cohort 
of elderly patients with advanced or metastatic cancer.  
In fact, in our study population as in Pilotto’s cohorts of, living alone was significantly associated 
with a worse MPI score: this relationship is explained by the fact that solitude is often associated 
with depression, a higher risk of falls, malnutrition, and financial problems; all these factors could 
influence a patient’s functional and clinical conditions. Solitude has proved to be a negative 
prognostic factor in a number of geriatric and oncological trials (Reuben, 1992; Kroenke, 2006). In 
the oncological setting, there is the added justification relating to the higher risk of treatment 
complications occurring in the absence of an active caregiver. This is an important issue in the 
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management of ECP and a potential target of intervention: preventing isolation could in itself 
improve the outcome in ECP.  
The burden of comorbidities, defined as the total number of associated diseases and the CIRS 
severity index, was significantly associated with the MPI score. Previous studies had already 
suggested the important prognostic value of comorbidities (Chen, 2007; Cudennec, 2009) in elderly 
patients, especially in association with functional decline (Zagonel, 2002). While comorbidity, as 
expressed by the CIRS-CI, seemed to be a good prognostic tool in geriatric patients, in this cohort 
of ECP the severity of their concomitant diseases and disorders (expressed by the CIRS-SI) became 
important. The present study showed that associated diseases retain their prognostic value in elderly 
patients with cancer too. Since it is essential to consider a patient’s comorbidities and their severity 
before preparing an oncological treatment plan – given the direct contraindications to the use of 
certain drugs and the impact on the patient’s life expectancy (Hurria, 2011) - this finding enhances 
the value of the MPI and its applicability in daily clinical practice. 
A significant association was likewise found between the MPI score and the ADL and IADL scores. 
For a long time now, functional status has been known to be an important risk factor in cancer 
patients (Wedding, 2007). In addition to its direct effect on overall survival, cancer patients with 
disabilities are less likely to receive a precise diagnosis and optimal treatment, and this has a further 
negative effect on their survival (Basso, 2011). 
Significant relationships were also found between decreasing body weight, decreasing BMI and 
worsening nutritional status and a worsening MPI score. Malnutrition is an important problem in 
cancer patients, because cancer itself causes loss of appetite and is implicated in the development of 
cachexia, and this influences the feasibility of cancer treatments. In elderly patients, functional and 
cognitive decline also raise the risk of malnutrition, and this condition further reduces the chances 
of treating their cancer (De Groot, 1998). 
Even when oncological treatments are possible, patients’ poor general conditions could reduce their 
tolerance of such therapy. Oncologic treatments can influence weight by causing vomiting and 
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changing the taste of foods, as shown in previous studies on the prognostic value of the MNA (De 
Groot, 1998). 
Limited mobilization is the main cause and consequence of functional decline that exposes patients 
to a higher risk of bed sores (Takahashi, 2008). By further impairing a patient’s mobility and 
nutritional status, cancer and its treatments may also contribute to the risk of bed scores, although 
no studies have explored the prognostic value of the Exton Smith Score in cancer patients. Bed 
sores are predictors of a higher mortality risk even in istituzionalized patients. In the present study, 
the patients’ ESS scores were consistent with their MPI scores and were of prognostic value, good 
ESS scores being associated with a 19% reduction in the 12-month mortality rate (HR 0.816, 95% 
CI 0.762-0.875, p<0.0001). 
Our cohort’s MPI scores correlated strongly with some of the geriatric tests not originally included 
in the prognostic index, i.e. the MMSE, GDS, CIRS-SI, VNS and CBI. The independent prognostic  
value of these geriatric tests was explored at both univariate and multivariate analysis. 
GDS emerged as a significant prognostic factor, patients with GDS ≥5 carrying a 3.6-fold higher 
mortality risk at 6 months. This result confirms the importance of assessing and treating depression 
in ECP with a view to improving the patients’ compliance with care and monitoring their perception 
of chemotherapy-related adverse events.  
The CBI was also found to predict 6- and 12-month mortality at univariate analysis, but its 
prognostic value was not confirmed at multivariate analysis, and the same applied to pain levels 
measured with the VNS.  
Surprisingly, the severity index calculated with the CIRS (not  included in the MPI model) was 
associated with a relevantly higher mortality risk and retained its prognostic significance at 
multivariate analysis.  
The assessment of predictors not included in the MPI model is not just an academic exercise, it  can 
pave the way to an integration of the MPI for use in cancer patients. This possibility is supported by 
the AUC in the ROC curves that we calculated, in which adjusting the MPI model not only for age 
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and gender, but also for CIRS-SI, MMSE, BSA, GDS, chemotherapy and a diagnosis of lung 
cancer, coincided with the best MPI performance, with an appreciable area under the ROC curve of 
0.914 at 6 months.  
The present study has some limitations. The sample size was relatively small considering the  
heterogeneity of the study population. In defining our inclusion criteria, we chose to consider a 
study population comparable with those observed in daily clinical practice because one of the most 
important criticisms of trials on ECP concerns their marked selectivity, which makes it difficult to 
transfer the results to routine clinical activity (Scher, 2012). Of course, our exploratory study cannot 
answer the question of which geriatric assessment is best in the context of geriatric oncology, but it 
certainly demonstrates that the MPI can be extremely useful in daily clinical practice for estimating 
overall survival and supporting oncological treatment decisions relating to elderly adults with 
locally advanced or metastatic cancer.  
Further studies on larger and more homogenous populations are needed to thoroughly assess the 
role of MPI in single cancer types, in the early stages of cancer disease, and in the setting of 
outpatient health care services. In the research setting, thanks to the marked standardization of the 
method and its clear clinimetric properties, the MPI may be applied more profitably than the  
traditional CGA in the context of clinical trials specifically designed for ECP (Balducci, 2003; 
Extermann, 2004). 
 
In conclusion, the present study confirms the prognostic value of the MPI in elderly patients with 
advanced cancer. In this specific setting, the MPI retained the same reliability and accuracy as 
reported in the original study by Pilotto et al. This index may consequently be used in daily clinical 
practice for the proper risk assessment of elderly patients with advanced cancer who are potential 
candidates for active oncological treatments. Further studies are nonetheless needed to confirm 
these findings in larger populations and assess the potential for integrating the MPI with the CIRS 
severity index and the GDS. 
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Table 2A Multidimensional Prognostic Index (MPI) score assigned to each domain based on the 
severity of the problems 
 
Assessment Problems 
 No (value = 0) Minor (value = 
0.5) 
Severe (value 
= 1) 
Activities of Daily Living (ADL)a 6–5 4–3 2–0 
Instrumental IADL (IADL)a 8–6 5–4 3–0 
Short Portable Mental Status Questionnaire 
(SPMSQ)b 
0–3 4–7 8–10 
Comorbidity-Index (CIRS-CI)c 0 1–2 ≥3 
Mini Nutritional Assessment (MNA)d ≥24 17–23.5 <17 
Exton–Smith Scale (ESS)e 16–20 10–15 5–9 
Number of Drugs 0–3 4–6 ≥7 
Social Condition Living with 
family 
Institutionalized Living alone 
a Number of active functional activities,  
b number of errors,  
c number of diseases,  
d MNA score: ≥24 = satisfactory nutritional status; 17–23.5 = at risk of malnutrition; <17 = malnutrition,  
e ESS score: 16–20 = minimum risk; 10–15 = moderate risk; 5–9 = high risk of developing scores 
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Table 2B: Characteristics of subjects by gender 
 
 Females (n = 88) Males (n = 72) p-value All (n=160) 
General and oncological characteristics    
Age  80.1 ± 5.7 (70-93) 78.4 ± 5.6 (69-92) 0.0729 79.4 ± 5.7 (69-93) 
Educational level 
(years) 
6.0 ± 3.2 (0-18) 6.9 ± 4.1 (0-19) 0.5547 6.4 ± 3.6 (0-19) 
Weight (kg) 61.9 ± 12.3 (30- 95) 73.6 ± 12.4 (47-103) <0.0001 67.2 ± 13.6 (30-103) 
Height (cm) 158.2 ± 7.3 (135-182) 172.0 ± 6.3 (155-185) <0.0001 164.5 ± 9.8 (135-185) 
BMI (Kg/m2) 24.7 ± 4.5 (15.5-42.2) 24.8 ± 3.7 (16.1-34.4) 0.8502 24.7 ± 4.2 (15.5-42.2) 
BSA (m2) 1.6 ± 0.2 (1.1-2.1) 1.9 ± 0.2 (1.5-2.2) <0.0001 1.7 ± 0.2 (1.1-2.2) 
CIRS-SI 1.7 ± 0.4 (1.1-3.1) 2.0 ± 0.5 (1.2-3.2) 0.0011 1.8 ± 0.4 (1.1-3.2) 
MMSE 23.3 ± 5.6 (9-30) 24.3 ± 4.4 (7-30) 0.5349 23.8 ± 5.1 (7-30) 
GDS 5.2 ± 3.1 (0-13) 4.3 ± 3.4 (0-12) 0.041 4.8 ± 3.3 (0-13) 
VNS 2.1 ± 2.7 (0-10) 2.9 ± 3.1 (0-10) 0.1226 2.5 ± 2.9 (0-10) 
CBI 7.5 ± 11.3 (0-47) 10.2 ± 13.5 (0-53) 0.1214 8.7 ± 12.4 (0-53) 
Site of primitive tumor   <0.0001  
Lung  3.4 31.9  16.3 
Stomach/Esophag
us 
13.6 8.3  11.3 
Breast 37.5 1.4  21.3 
Colon-rectal 31.8 40.3  35.6 
Other sites 13.6 18.1  15.6 
Metastasis 58.1 62.5 0.5772 60.1 
Oncological Treatments     
Surgery 31.8 25.0 0.3431 28.8 
Chemotherapy 46.6 52.8 0.4361 49.4 
Endocrine-therapy 17.1 1.4 0.0009 10.0 
Radiotherapy  8.0 1.4 0.2256 10.0 
None 9.1 20.8 0.0352 14.4 
MPI Domains     
MNA 20.2 ± 5.5 (6.5-29) 20.7 ± 5.7 (8-29) 0.4208 20.4 ± 5.6 (6.5-29) 
ADL  4.7 ± 2.1 (0-6) 4.5 ± 2.0 (0-6) 0.3923 4.6 ± 2.0 (0-6) 
IADL 5.3± 2.8 (0-8) 5.8 ± 2.6 (0-8) 0.2811 5.5 ± 2.7 (0-8) 
CIRS-CI 2.9 ± 1.6 (0-8) 4.2 ± 2.1 (1-9) 0.0002 3.5 ± 1.9 (0-9) 
ESS 17.1 ± 2.8 (9-20) 17.5 ± 2.8 (8-20) 0.4461 17.3 ± 2.8 (8-20) 
SPMSQ 1.8 ± 2.1 (0-9) 1.5 ± 2.0 (0-10) 0.2377 1.7 ± 2.1 (0-10) 
Social Condition   0.0010  
Living alone 35.2 12.5  25.0 
Living with family 61.4 86.1  72.5 
Institutionalized 3.4 1.4  2.5 
Number of Drugs   0.2392  
0-3 drugs 52.3 38.9  46.3 
4-6 drugs 33.0 41.7  36.9 
≥ 7 drugs 14.8 19.4  16.9 
MPI 0.35 ± 0.22 (0.06-0.88) 0.34 ± 0.20 (0.06-0.75) 0.7919 0.35 ± 0.21 (0.06-0.88) 
Mortality     
6 months 33.0 36.1 0.6758 34.4 
12 months 46.6 47.2 0.9365 46.9 
Data are presented as % or mean±SD (min-max) 
NS: not significant differences 
Abbreviation: BMI, Body Max Index; BSA, Body Surface Area; CIRS-SI, Cumulative Illness Rating Scale-
Severity Index; MMSE Mini-Mental State Examination, GDS Geriatric Depression Scale short form, VNS 
Visual Numeric Scale, CBI Caregiver Burden Inventory, MNA, Mini Nutritional Assessment; ADL, 
Activities of Daily Living; IADL, Instrumental Activities of Daily Living; CIRS-CI, Cumulative Illness 
Rating Scale-Comorbidity Index; ESS, Exton Smith Scale; SPMSQ, Short Portable Mental Status 
Questionnaire; MPI, Multidimensional Prognostic Index.  
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Table 2C: Characteristics of subjects according to MPI grade 
 
 MPI 
 
Low  (n = 96) Moderate (n = 48) Severe (n = 16) p-value 
General and oncological characteristics    
Age 78.2 ± 4.9 (69-89) 81.3 ± 6.0 (71-92) 81.0 ± 7.5 (69-93) 0.0089 
Gender    0.2170 
Female  57.3 45.8 68.8  
Male  42.7 54.2 31.2  
Educational Level (ys) 6.2 ± 3.3 (0-19) 6.1 ± 3.7 (0-19) 8.6 ± 4.9 (3-18) 0.1425 
Weight (Kg)  70.2 ± 13.5 (40-102) 63.5 ± 13.3 (30-103) 60.2 ± 9.8 (34.8-75) 0.0018 
Height (cm) 164.5 ± 9.8 (145-185) 164.4 ± 10.0 (135-182) 164.7 ± 9.6 (150-180) 0.9752 
BMI (Kg/m2) 25.8 ± 4.1 (17.6-42.2) 
 
23.4 ± 3.9 (16.1-34.4) 22.1 ± 2.7 (15.5-27.3) <0.0001 
BSA (m2) 1.8 ± 0.2 (1.3-2.2) 1.7 ± 0.2 (1.1-2.2) 1.7 ± 0.2 (1.2-1.9) 0.0362 
CIRS-SI 1.7 ± 0.4 (1.1-3.2) 2.0 ± 0.5 (1.2-3.1) 2.1 ± 0.5 (1.3-3.1) 0.0002 
MMSE 25.5 ± 4.0 (14-30) 22.9 ± 5.0 (7-30) 17.4 ± 5.5 (9-27) <0.0001 
GDS 3.8 ± 2.9 (0-12) 5.8 ± 3.2 (0-12) 7.5 ± 3.5 (0-13) <0.0001 
VNS 1.6 ± 2.3 (0-8) 3.4 ± 2.9 (0-10) 4.4 ± 4.1 (0-10) 0.0001 
CBI 4.0 ± 7.3 (0-33) 13.5 ± 14.4 (0-53) 23.3 ± 14.3 (0-48) <0.0001 
Site of primitive tumor    <0.0001 
Lung  13.5 22.9 12.5  
Stomach/Esophagus 9.4 12.5 18.8  
Breast 28.1 12.5 6.3  
Colon-rectal 40.6 27.1 31.3  
Other sites 8.3 25.0 31.3  
Metastasis 63.5 54.2 50.0 0.5464 
Oncological Treatments     
Surgery 25.0 31.3 43.8 0.2776 
Chemotherapy 55.2 41.7 37.5 0.1873 
Endocrine-therapy 12.5 8.3 0.0 0.3514 
Radiotherapy  7.3 18.8 6.3 0.0894 
None 89.6 81.3 75.0 0.1651 
MPI Domains     
MNA 23.2 ± 3.7 (13.0-29.0) 16.9 ± 5.3 (6.5-25.0) 13.8 ± 4.5 (8.5-23.0) <0.0001 
ADL 
 
5.9 ± 0.4 (4-6) 3.3 ± 1.9 (0-6) 1.0 ± 1.0 (0-2) <0.0001 
IADL 7.1 ± 1.4 (3-8) 3.6 ± 2.5 (0-8) 1.6 ± 1.7 (0-5) <0.0001 
CIRS-CI 3.0 ± 1.6 (0-8) 4.0 ± 2.1 (1-9) 4.7 ± 2.3 (1-8) 0.0016 
ESS 18.9 ± 1.5 (13-20) 15.6 ± 2.0 (12-20) 12.6 ± 2.8 (8-18) <0.0001 
SPMSQ 1.0 ± 1.4 (0-6) 2.0 ± 2.1 (0-9) 4.6 ± 2.6 (0-10) <0.0001 
Social Condition 
 
   0.0148 
Living alone  19.8 29.2 43.8  
Living with family  78.1 70.8 43.8  
Institutionalized  2.1 0.0 12.5  
Number of Drugs    <0.0001 
0-3 drugs 63.5 25.0 6.3  
4-6 drugs 32.3 45.8 37.5  
≥ 7 drugs 4.2 29.2 56.3  
MPI     
MPI 0.20 ± 0.08 (0.06-0.31) 0.50 ± 0.09 (0.38-0.64) 0.75 ± 0.07 (0.69-
0.88) 
- 
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Mortality     
6 months 16.7 56.3 75.0 <0.0001 
12 months     29.2 70.8 81.3 <0.0001 
Data are presented as % or mean±SD (min-max) 
NS: not significant differences.  
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Table 2D: Univariate Hazard Risks of mortality, age- and sex-adjusted, according to the MPI, the 
individual factors used to calculate the MPI and other possible mortality predictors after 6 months 
and 12 months of follow-up 
 
Predictors 6 months  12 months 
 HR 95% CI p-value  HR 95% CI p-value 
General and oncological characteristics      
Educational Level 
(years) 
1.039 0.966-1.117 0.3076  1.051 0.989-1.118 0.1111 
BSA (m2) 0.062 0.014-0.277 0.0003  0.095 0.026-0.356 0.0005 
CIRS-SI 4.804 2.681-8.608 <0.0001  3.984 2.358-6.732 <0.0001 
MMSE 0.959 0.913-1.007 0.0944  0.981 0.938-1.025 0.3893 
GDS 1.241 1.141-1.350 <0.0001  1.186 1.101-1.277 <0.0001 
VNS 1.147 1.055-1.246 0.0013  1.142 1.063-1.227 0.0003 
CBI 1.037 1.018-1.056 <0.0001  1.032 1.016-1.049 0.0001 
Site of primitive tumor   <0.0001    0.0001 
Lung  1.111 0.503-2.245 0.7955  1.057 0.545-2.168 0.8789 
Stomach/Esophagus 1.098 0.492-2.499 0.8202  0.949 0.448-2.028 0.8924 
Breast 0.308 0.123-0.768 0.0116  0.323 0.148-0.706 0.0046 
Colon-rectal 0.170 0.068-0.425 0.0001  0.296 0.150-0.585 0.0005 
Other sites 1    1   
Metastasis 1.934 1.059-3.530 0.0318  1.993 1.197-3.320 0.0080 
Oncological Treatments        
Chemotherapy 1.468 0.857-2.514 0.1618  1.693 1.064-2.693 0.0262 
Radiotherapy  1.568 0.760-3.236 0.2234  1.344 0.687-2.630 0.3879 
Endocrine-therapy 0.431 0.131-1.416 0.1657  0.493 0.195-1.250 0.1364 
Surgery 0.605 0.312-1.172 0.1361  0.572 0.324-1.008 0.0534 
MPI Domains        
MNA 0.838 0.799-0.879 <0.0001  0.850 0.816-0.885 <0.0001 
ADL 0.689 0.616-0.771 <0.0001  0.724 0.656-0.799 <0.0001 
IADL 0.753 0.687-0.825 <0.0001  0.798 0.737-0.864 <0.0001 
CIRS-CI 1.307 1.138-1.500 <0.0001  1.246 1.105-1.406 <0.0001 
ESS 0.783 0.726-0.845 <0.0001  0.816 0.762-0.875 <0.0001 
SPMSQ 1.082 0.957-1.224 0.2082  1.060 0.949-1.184 0.3010 
Social Condition   0.7304    0.7133 
Living with family  1    1   
Living alone  1.182 0.632-2.213 0.6003  1.246 0.732-2.121 0.4179 
Institutionalized  1.632 0.385-6.912 0.5059  1.199 0.287-5.000 0.8036 
Number of Medications   0.1126    0.1752 
0-3 drugs 1    1   
4-6 drugs 1.395 0.762-2.553 0.2810  1.271 0.761-2.120 0.3593 
≥ 7 drugs 2.143 1.044-4.399 0.0378  1.802 0.967-3.357 0.0638 
MPI        
MPI   <0.0001    <0.0001 
Low 1    1   
Moderate 4.358 2.269-8.270 <0.0001  3.565 2.1116-6.006 <0.0001 
Severe 8.094 3.749-17.475 <0.0001  5.655 2.866-11.158 <0.0001 
MPI* 3.595 2.492-5.188 <0.0001  2.937 2.142-4.027 <0.0001 
*0.3 units increase in MPI 
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Table 2E: Multivariate Cox regression models age and sex adjusted for mortality after 6 months 
and 12 months of follow-up 
 
Predictors 6 months  12 months 
 HR 95% CI p-value  HR 95% CI p-value 
MPI* 5.959 3.214-11.048 <0.0001  5.130 2.946-8.934 <0.0001 
CIRS-SI 5.010 2.167-10.553 <0.0001  5.060 2.543-
10.070 
<0.0001 
BSA 0.009 0.001-0.082 <0.0001  0.039 0.007-0.218 0.0002 
GDS (≥5) 3.621 1.773-7.395 0.0004  2.605 1.501-4.519 0.0007 
MMSE 1.126 1.043-1.215 0.0024  1.128 1.054-1.207 0.0005 
Chemotherapy 3.201 1.662-6.168 0.0005  3.559 2.010-6.301 <0.0001 
Site (lung) 3.456 1.681-7.104 0.0007  2.701 1.431-5.099 0.0022 
 
*0.3 units increase in MPI 
 0.1 units increase in MPI: HR=1.813, 95% CI=1.476-2.227 after 6 months, HR=1.725, 95% 
CI=1.434-2.075 after 12 months of follow-up 
 0.2 units increase in MPI: HR=3.287, 95% CI=2.178-4.961 after 6 months, HR=2.975, 95% 
CI=2.055-4.305 after 12 months of follow-up 
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Table 2F: Predictive performance of the MPI for 6 months and 12 months of overall survival 
 6 months Survival  12 months Survival 
 AUC ROC 95% CI p-value  
AUC 
ROC 95% CI p-value 
Unadjusted model 0.815 0.746-0.884 <0.0001  0.778 0.706-0.849 <0.0001 
Age adjusted model 0.817 0.748-0.886 <0.0001  0.780 0.709-0.852 <0.0001 
Age and sex adjusted 
model 0.814 0.743-0.884 <0.0001  0.778 0.706-0.850 <0.0001 
Age and sex adjusted 
model + other mortality 
predictors* 
0.914 0.869-0.959 <0.0001  0.874 0.819-0.928 <0.0001 
 
AUC ROC: area under the receiver operating characteristics curve 
* CIRS-SI, BSA, GDS (≥5), MMSE, Chemotherapy Treatment, Site (lung) 
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Figure 2A: age and sex adjusted survival curves for different grades of MPI at 6-month (left) and 
12-month (right). 
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CHAPTER 3 
The Toxicity Risk 
ESTIMATING THE RISK OF CHEMOTHERAPY TOXICITY IN VULNERABLE 
ELDERLY CANCER PATIENTS: THE ROLE OF VULNERABLE ELDERS 
SURVEY-13 (VES-13) 
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3.1 BACKGROUND AND AIMS  
Comprehensive geriatric assessment (CGA) is a multidimensional tool used by 
geriatricians and oncologists to detect and evaluate multiple age-related problems of 
general health and all of the functional, cognitive, social and psychological parameters of 
older subjects, and to plan and coordinate appropriate  interventions (Rubenstein, 1984). 
Such approach has already been shown that it can offer considerable benefits in various 
settings and medical conditions and, in oncology, CGA can provide clinical informations 
that are not revealed by performance status (Monfardini, 1996; Repetto, 2002; Luciani, 
2012). Recent oncological studies have shown that some geriatric parameters are 
predictive of chemotherapy toxicity, and specific scores have been identified in order to 
help physicians in their everyday clinical practice (Extermann, 2012; Falandry, 2013; 
Hurria, 2010).  
However, as CGA is time consuming and can rarely be used routinely by oncologists, 
some short screening instruments have been validated for elderly patients with cancer 
(Balducci, 2010). The most widely studied of these is the Vulnerable Elders Survey 
(VES-13) (Molina-Garrido, 2011; Owusu, 2011; Luciani, 2010; Mohile, 2007; Biganzoli, 
2013; Pottel, 2012), a 13-item function-based scoring system that considers age, self-
rated health, limitations in physical function and functional disabilities, and provides a 
simple and clinically relevant means of identifying older people with an increased degree 
of vulnerability (Min, 2006) ; its  geriatric validation showed that vulnerable patients 
were at 4.2-fold greater risk of dying during the following two years (Saliba, 2001). In 
comparison with a full CGA, it has good sensitivity and acceptable specificity (Luciani, 
2010), but there is not consistent medical literature regarding its ability to predict 
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chemotherapy toxicity. We therefore collected the clinical records of patients enrolled in 
four published clinical trials of VES-13 (Luciani, 2010; Biganzoli, 2013; castagneto, 
2013; Falci, 2009) with the aim of evaluating its accuracy in predicting the risk of grade 
3/4 toxicity in elderly patients undergoing chemotherapy.  
 
3.2 PATIENTS AND METHODS 
 
3.2.1 Patients 
The study involved patients aged >70 years with a histologically or cytologically 
confirmed diagnosis of a solid or hematological tumor able to comprehend Italian 
language and no other active cancer diagnosis. All of the patients underwent a VES-13 
evaluation by a trained physician before receiving cancer treatment.  
The study was approved by the Ethics Committee of the coordinating centre. 
 
3.2.2 Functional status 
The patients with a VES-13 score of ≥3 were considered vulnerable; as VES-13 classifies 
all patients aged >85 years as vulnerable, these reach a score of 3 solely on the grounds of 
age. Performance status was expressed using Zubrod’s 0-5 scale, with zero being the best, 
4 the worst and 5 classifying death. 
 
3.2.3 Comorbidities 
Comorbidities were recorded as a total number and assessed using the Cumulative Illness 
Rating Scale for Geriatrics (CIRS-G), which rates 14 conditions on the basis of their 
severity (0 = no problem; 4 = severe or life threatening). The results are expressed as a 
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total score and a comorbidity index (total score divided by the number of affected organs 
and systems) (Miller, 1992). An index of >3 and/or a severity category of 3-4 was 
considered a sign of disability. 
 
3.2.4 Medications 
The number and type of medications (including those used for pain and nausea, as well as 
over-the-counter medications) were recorded at the time of the evaluation. 
 
3.2.5 Cognitive and social status 
Cognitive status was assessed using Folstein’s Mini-Mental State Evaluation (MMSE). A 
score of <24 suggested a cognitive impairment. 
The social status assessment included the patient’s living conditions (alone, with a family 
member, with friends, or in an assisted residence), and the presence and adequacy of a 
designated caregiver. 
 
3.2.6 Nutritional status 
Nutritional status was preliminarily assessed by means of the Mini-Nutritional 
Assessment®. If the total score was <17, the patients were considered at risk of 
malnutrition (Gerber, 2003; Barone, 2003; Bleda, 2002). 
 
3.2.7 Treatment 
All of the patients were allowed to receive chemotherapy for early or advanced disease in 
accordance with the international guidelines for each specific cancer type. A record was 
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kept of the type of chemotherapy, the number of cycles, the number of dose reductions, 
the reason for each reduction, the number of treatment interruptions, and the patient’s 
response. Toxicity was assessed using the Common Terminology Criteria for Adverse 
Events (CTCAE) v. 4.0, and grade 3-4 hematological and non-hematological toxicities 
were considered in the analysis.  
 
3.2.8 Statistical analysis 
Characteristics of the studied sample were summarized overall and by group defined by 
VES-13 score, using  mean, standard deviation (SD) and minimum-maximum values for 
continuous variables, absolute and relative frequencies for categorical variables. 
Comparisons of baseline and tumor characteristics between vulnerable and non 
vulnerable groups were made by Chi-square test or Fisher test for categorical variables or 
Wilcoxon test for continuous ones. A logistic regression model was used for univariate 
and multivariate analyses to test demographic characteristics and clinical features for 
their association with the risk of grade 3-4 toxicity occurrence. Variables found to be 
possibly associated (p<0.15) or biologically relevant in the univariate model were 
considered for multivariate analysis. Results are expressed as odds ratios (ORs) with their  
95% confidence intervals (95% CIs).  Unless otherwise specified, statistical significance 
was set at p=0.05 for a bilateral test. Analyses were carried out with SAS Software, 
version 9.2 (SAS Institute, Cary, NC). 
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3.3 RESULTS 
 
3.3.1 Patients 
The study involved 648 Caucasian patients aged >70 years, whose baseline 
characteristics are shown in Table 3A. Their mean age was 76.2 (SD 4.5), ranging from 
66 to 90  years, 336 (51.9%) were female, and all were capable of speaking and reading 
Italian language. Most (58.8%) of them were married and 91.0% had an adequate 
caregiver. They had a median number of two comorbidities (ranging from 0 to 9), and 
were taking a median number of three medications (ranging from 0 to 13). The most 
prevalent comorbidities affected the cardiovascular system, and the prevalent medication 
categories were antihypertensive and cardiovascular drugs. Lung as well as colorectal 
cancer each accounted for 26.1% of the  patients; breast and ovarian cancer accounted for 
8.6%  and 9.7% of  patients respectively. 
 
3.3.2 VES-13 and treatment 
VES-13 identified 287 of the patients (44.3%) as vulnerable: i.e. with a score of >3 (Tab. 
3A). Their mean age was 77.6 (SD 4.9), ranging from 67 to 90 years; 57.1% were female 
with a median number of three comorbidities (ranging from 0 to 9). Their performance 
status and CIRS index were both worse than those of the non-vulnerable patients (Tab. 
3B), and fewer received polychemotherapy (38.3% vs. 62.6%, p < 0.001). Most of the 
patients received first-line and adjuvant chemotherapy (Tab. 3B); only 1.4% received 
radiotherapy in a sequantial schedule. 
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3.3.3 Toxicity 
As shown in Table 3C, grade 3-4 hematological and non-hematological toxicities were 
more prevalent in the vulnerable subjects (35.2% vs 20.8%, p <0.0001, and 18.5% vs 
10.8%, p = 0.0055). A total of 120 vulnerable patients (41.8%) underwent dose 
reductions,  which were due to toxicity in 61 cases (50.8%); 86 patients (30.0%) 
interrupted their treatment, mainly because of disease progression (44 patients, 51.2%).  
 
3.3.4 VES-13 and toxicity 
At  univariate analysis VES-13 score, sex, age, propensity score, MMSE score and CIRS 
score resulted biologically relevant, possibly or significantly associated with grade 3-4 
toxicity occurrence, therefore they were selected for multivariate assessment. In the 
multivariate model, vulnerable patients (OR 2.15, 95% CI 1.46-3.17; p<0.001) and 
females (OR 1.53, 95% CI 1.05-2.23; p=0.025) had a higher risk of hematological 
toxicity, whereas increase of CIRS appear to be protective (OR 0.90, 95%CI 0.83-0.97; 
p=0.008) (Table 3D). 
The  variables included in the multivariate analysis of non-hematological toxicity (Table 
3D) were age, performance status, VES-13 score, and the presence of metastasis. The 
vulnerable patients had an OR of 1.66 (95% CI 1.02-2.72; p = 0.043) and those with a 
metastatic disease  had an OR of 0.59 (95% CI 0.37-0.94; p = 0.026). 
The Forest plot by age subgroup (Fig. 3A) showed an higher risk of toxicity with 
increasing class of age. For non-hematological toxicity (Fig. 3B) this trend is less clear 
and no effects heterogeneity was observed between age subgroups.  
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3.4 DISCUSSION 
 
The aim of this study was to assess the role of VES-13 (a screening instrument that has 
been validated in geriatric patients and is recommended by the NCCN clinical practice 
guidelines for senior adult cancer subjects) in predicting the risk of chemotherapy toxicity 
in a sample of elderly cancer patients undergoing chemotherapy. The patients identified 
as vulnerable by the VES-13 had a statistically significant higher risk of developing both 
hematological (OR 2.15, 95%CI 1.46-3.17; p<0.001) and non-hematological toxicity (OR 
1.66, 95%CI 1.02-2.72; p=0.043). These risk increases progressively with the aging of 
the population, particularly for haematological toxicity. 
In clinical practice, medical oncologists do need to identify the elderly patients who are at 
higher risk of developing toxicity due to cancer treatment. In two pilot studies, 
Extermann et al. (Extermann, 2002; Extermann, 2004) developed and validated the 
MAX2 index as a a means of comparing the average risk of severe toxicity due to various 
chemotherapy regimens, and this was recently included in a larger trial in which a 
number of clinical and geriatric items constituted a scoring system for predicting 
treatment toxicity (the CRASH score) (Extermann, 2012). Another study of a large 
sample of elderly patients found that some geriatric dimensions (the CARG score) can 
predict toxicity (Hurria, 2011). Although methodologically different, these two studies 
showed for the first time that clinico-biological variables (including those based on a 
geriatric evaluation) can play an important role in the menagement of chemotherapy in 
elderly cancer patients.  
VES-13 was developed as a rapid method of identifying age-related problems and 
vulnerable subjects (Saliba, 2001) and has been validated in oncology as a short 
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instrument of distinguishing patients who should undergo a full geriatric evaluation from 
those who do not need to do so (Luciani, 2010; Biganzoli 2013; Extermann 2007). 
However, our findings indicate an important new role of the VES-13 in the management 
of elderly cancer patients which, to the best of our knowledge, has been described in only 
one previous study (Stoke, 2012).  
Although the VES-13 was not originally designed to answer specific oncological 
questions, it has hereafter demonstrated an high capacity to estimate the overall risk of 
toxicity in elderly patients, especially in patients over 75 years old. The importance of our 
findings is reinforced by the fact that we used the most widely studied and previously 
validated assessment instrument in geriatric oncology. However, one point should not be 
ruled out: the VES-13 is widely used for screening purposes in everyday clinical practice 
and allows a pre-assesment of patients that eventually require a full geriatric evaluation 
(Rodin, 2007). Whenever possible, we encourage the use of a CGA in accordance with 
the guidelines. However, this time-consuming evaluation is not practicable in most 
oncological centres and a brief assessment instrument such as the VES-13 could help 
physicans to optimise assessment times and choose the most appropriate treatment. Fifty-
five percent of the patients in our series were classified as being non-vulnerable, which 
means that a full CGA is potentially not required by more than half of the patients 
attending oncological centres. 
Performance status (PS) is usually a useful means of assessing the functional status of 
older patients and making treatment decisions, but we found that it did not play any 
significant role in the estimation of cancer treatment risk. However, as one possible 
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reason for this is that only 11% of our patients had a PS of 2-3, we do not believe that PS 
should be excluded from the assessment of elderly cancer patients. 
A second interesting finding of our analysis is the significant and apparently protective 
impact of comorbidity scores (CIRS-G) on toxicity. Historically, comorbidities and 
functional status have been considered two different models of evaluation that have a 
parallel impact on a patient’s clinical status, although some trials have shown that they 
should be evaluated independently even if they have a combined effect (Extermann, 
1998). On the basis of our findings, we believe that CIRS-G is an instrument should be 
used with caution when assessing the potential risk of chemotherapy toxicity. 
In conclusion, our data indicate that, together with other scores, the VES-13 can be used 
in the assessment and risk management of elderly cancer patients undergoing 
chemotherapy. Future studies should be planned with the aim of prospectively comparing 
the various instruments or scores currently used in geriatric oncology in order to 
determine which are most appropriate in clinical practice when considering specific 
aspects of patient management (e.g. toxicity, overall survival, active life expectancy, or 
the quality of life).                      
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Table 3A. Demographic and clinical characteristics by VES -13 scores of eligible 
patients. 
 
Variable VES-13 <3 VES-13 ≥3 Overall* P-value 
Number of patients - N (%) 361 (55.7) 287 (44.3) 648 (100) 0.004§ 
Age in years – Mean (SD) 75.1 (3.8) 77.6 (4.9) 76.2 (4.5) <0.001# 
                          Min-Max 66-84 67-90 66-90  
Female sex - N (%) 172 (47.6) 164 (57.1) 336 (51.9) 0.016§ 
Marital status - N (%)    0.003¤ 
Not married 25 (7.2) 11 (3.9) 36 (5.8)  
Married 230 (66.3) 138 (49.5) 368 (58.8)  
Divorced 5 (1.4) 3 (1.1) 8 (1.3)  
Widow/er 87 (25.1) 127 (45.5) 214 (34.2)  
Unknown 14 8 22  
Education - N (%)    0.792§ 
No education 3 (0.8) 4 (1.4) 7 (1.1)  
Primary 217 (60.3) 170 (59.2) 387 (59.8)  
Secondary 100 (27.8) 84 (29.3) 184 (28.4)  
College 26 (7.2) 22 (7.7) 48 (7.4)  
University 14 (3.9) 7 (2.4) 21 (3.2)  
Unknown 1 - 1  
Caregiver presence – N (%) 323 (89.5) 267 (93.0) 590 (91.0) 0.115§ 
Comorbidities  – Median 2 3 2 <0.001# 
                              Min-Max 0-8 0-9 0-9  
Medications  – Median 3 4 3 <0.001# 
                          Min-Max 0-12 0-13 0-13  
ECOG  PS - N (%)    <0.001§ 
0-1 349 (96.7) 227 (79.4) 576 (89.0)  
2-3 12 (3.3) 59 (20.6) 71 (11.0)  
Unknown - 1 1  
CIRS (Total) – Mean (SD) 3.6 (2.4) 3.8 (2.5) 3.7 (2.4) 0.426# 
                           Min-Max 0-12 0-12 0-12  
CIRS (Index) – Mean (SD) 1.6 (0.6) 1.7 (0.5) 1.6 (0.5) 0.031# 
                           Min-Max 0-3 0-2.7 0-3  
MNA- N (%)    <0.001§ 
0 307 (85.0) 206 (71.8) 513 (79.2)  
1 54 (15.0) 81 (28.2) 135 (20.8)  
MMSE – Mean (SD) 27.8 (2.2) 27.4 (2.8) 27.7 (2.5) 0.002# 
                Min-Max 17-30 16.3-52 16.3-52  
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Legends of table 3A: PS=Performance Status; VES-13: Vulnerable Elders Survey. 
* The percentages in the column “Overall” are calculated having as denominator the total 
number of patients 
§ Chi-square Test 
# Wilcoxon Rank-Sum Test 
¤ Fisher’s Exact Test  
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Table 3B. Tumour and treatment characteristics by VES-13 in the eligible patients 
Variable VES-13 < 3 VES-13 ≥ 3 Overall* P-value 
Primary tumor site – N (%)    0.003§ 
Colon-rectum 110 (30.5) 59 (20.6) 169 (26.1)  
Endometrium 20 (5.5) 13 (4.5) 33 (5.1)  
Breast 36 (10.0) 20 (7.0) 56 (8.6)  
Ovary 23 (6.4) 40 (13.9) 63 (9.7)  
Pancreas 17 (4.7) 21 (7.3) 38 (5.9)  
Lung 88 (24.4) 81 (28.2) 169 (26.1)  
Other 67 (18.6) 53 (18.5) 120 (18.5)  
Metastasis– N (%) 238 (65.9) 218 (76.0) 456 (70.4) 0.006§ 
Chemotherapy – N (%)    < 0.001§ 
Monochemotherapy  135 (37.4) 177 (61.7) 312 (48.1)  
Polychemotherapy 226 (62.6) 110 (38.3) 336 (51.9)  
Response – N (%)    0.001§ 
CR 138 (38.2) 78 (27.2) 216 (33.3)  
PR 78 (21.6) 50 (17.4) 128 (19.8)  
NC 59 (16.3) 56 (19.5) 115 (17.7)  
PRO 86 (23.8) 103 (35.9) 189 (29.2)  
Treatment type - N (%)    0.311¤ 
CT 354 (98.1) 285 (99.3) 639 (98.6)  
CT+RT 7 (1.9) 2 (0.7) 9 (1.4)  
Chemotherapy type - N (%)    0.093¤ 
Neoadjuvant therapy 8 (2.2) 4 (1.4) 12 (1.9)  
Adjuvant therapy 123 (34.1) 68 (23.7) 191 (29.5)  
First line 220 (60.9) 213 (74.2) 433 (66.8)  
Second line 8 (2.2) - (0.0) 8 (1.2)  
Third line 1 (0.3) 2 (0.7) 3 (0.5)  
Fifth line 1 (0.3) - (0.0) 1 (0.2)  
Treatment type - N (%)     
Neoadjuvant therapy:     
- CT 7 (1.9) 4 (1.4) 11 (1.7)  
- CT+RT 1 (0.3) - (0.0) 1 (0.2)  
Adjuvant therapy:     
- CT 118 (32.7) 66 (23.0) 184 (28.4)  
- CT+RT 5 (1.4) 2 (0.7) 7 (1.1)  
     
 76 
First line:     
- CT 219 (60.7) 213 (74.2) 432 (66.7)  
- CT+RT 1 (0.3) - (0.0) 1 (0.2)  
Second line:     
- CT 8 (2.2) - (0.0) 8 (1.2)  
Third line:     
- CT 1 (0.3) 2 (0.7) 3 (0.5)  
Fifth line:     
- CT 1 (0.3) - (0.0) 1 (0.2)  
* The percentages in the column “Overall” are calculated having as denominator the total 
number of patients 
§ Chi-square Test 
¤ Fisher’s Exact Test 
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Table 3C. Treatment compliance and toxicity 
Variable VES-13 < 3 VES-13 ≥ 3 Overall* P-value** 
Dose Reduction  
(First Cycle) - N (%) 50 (13.9) 37 (12.9) 87 (13.4) 0.722
§ 
Dose Reduction - N (%) 131 (36.4) 120 (41.8) 251 (38.8) 0.160§ 
Unknown 1 - 1  
Cause of Dose Reduction  
– N (%) 
   0.788¤ 
Toxicity 70 (53.8) 61 (50.8) 131 (52.4)  
Acute event 1 (0.8) - (0.0) 1 (0.4)  
Medical decision 42 (32.2) 41 (34.2) 83 (33.2)  
Subject decision 6 (4.6) 3 (2.5) 9 (3.6)  
Progression 10 (7.7) 14 (11.7) 24 (9.6)  
Death 1 (0.8) 1 (0.8) 2 (0.8)  
Unknown 1 - 1  
Treatment Interruption – N 
(%) 106 (29.4) 86 (30.0) 192 (29.6) 0.868
§ 
Cause of Treatment 
Interruption – N (%)    0.025
¤ 
Toxicity 33 (31.1) 23 (26.7) 56 (29.2)  
Acute event 1 (0.9) 2 (2.3) 3 (1.6)  
Medical decision 17 (16.0) 3 (3.5) 20 (10.4)  
Subject decision 16 (15.1) 12 (14.0) 28 (14.6)  
Progression 36 (34.0) 44 (51.2) 80 (41.7)  
Death 2 (1.9) 2 (2.3) 4 (2.1)  
Other 1 (0.9) - (0.0) 1 (0.5)  
Haematological Toxicity 
(Grade 3-4) – N (%) 75 (20.8) 101 (35.2) 176 (27.2)  
Non Haematological Toxicity 
(Grade 3-4) – N (%) 39 (10.8) 53 (18.5) 92 (14.2)  
 
* The percentages in the column “Overall” are calculated having as denominator the total 
number of patients 
§ Chi-square Test 
¤ Fisher’s Exact Test 
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Table 3D. Effect of different parameters on hematological toxicity. Univariate and multivariate logistic regression models 
 
 
 
 
 
 Haematological toxicity Non haematological toxicity 
 Univariate analysis Multivariate analysis Univariate analysis Multivariate analysis 
Variable OR (95%CI) p-value OR (95%CI) p-value OR (95%CI) p-value OR (95%CI) p-value 
Female sex 1.81 (1.27-2.59) 0.001 1.53 (1.05-2.23) 0.025 1.18 (0.76-1.84) 0.458 Not included 
Age (for each 1-year increase)  0.99 (0.96-1.03) 0.762 0.97 (0.93-1.01) 0.189 1.05 (1.00-1.10) 0.052 1.03 (0.98-1.09) 0.184 
Ves13 (for each 1-unit increase) 1.10 (1.04-1.18) 0.003 Not included 1.09 (1.01-1.17) 0.037 Not included 
Ves13 ≥ 3 2.07 (1.46-2.94) <0.001 2.15 (1.46-3.17) <0.001 1.87 (1.20-2.92) 0.006 1.66 (1.02-2.72) 0.043 
Presence of metastasis 1.17 (0.80-1.72) 0.423 Not included 0.64 (0.41-1.02) 0.058 0.59 (0.37- 0.94) 0.026 
ECOG PS         
0-1 (reference) 1  1  1    
2-3 1.90 (1.14-3.17) 0.014 1.37 (0.79-2.37) 0.270 2.10 (1.16-3.82) 0.015 1.64 (0.87-3.08) 0.126 
CIRS (Total) (for each 1-unit 
increase) 0.89 (0.82-0.96) 0.003 0.90 (0.83-0.97) 0.008 0.95 (0.87-1.05) 0.320 Not included 
CIRS (Index) (for each 1-unit 
increase) 1.12 (0.80-1.56) 0.504 Not included 0.76 (0.51-1.13) 0.171 Not included 
MNA positive 1.07 (0.70-1.63) 0.772 Not included 0.99 (0.57-1.70) 0.963 Not included 
MMSE (for each 1-unit increase) 1.06 (0.99-1.14 ) 0.123 1.08 (1.00-1.17) 0.043 1.05 (0.96-1.14) 0.325 Not included 
Response        
CR+PR (reference) 1   1   
NC+PRO 0.89 (0.63-1.27) 0.528 Not included 0.99 (0.64-1.54) 0.971 Not included 
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Figure 3A. Forest plot of ORs (VES-13 ≥3 vs VES-13 <3) of hematological toxicity by age group 
 
 
 
Figure 3B. Forest plot of ORs (VES-13 ≥3 vs VES-13 <3) of non-hematological toxicity by age group 
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The Research Activity, described in the present thesis, has been devoted to shed light into some 
critical aspects of Geriatric Oncology. 
 Despite cancers in the elderly represents an important epidemiological issue, for decades cancer 
patients aged 70 years or more have been excluded from clinical trials and from the relevant 
progresses in anticancer treatments that became available to younger adults.  
The undertreatment of elderly cancer patients, due to underestimation of survival benefits and 
overestimation of toxicity risks, is still a relevant problem as well as the fact that less than 10% of 
cancer centres in Italy have a special unit dedicated to the management of elderly patients. 
Certainly, a better knowledge of the relationship between ageing and cancer is essential to  optimize 
the cancer treatment in aged patients and both translational and clinical research should be 
performed to accelerate the progresses in Geriatric Oncology.  
The first study reported in the present thesis was the first to approach the problem of 
immunesenescence in elderly cancer patients. The study provided the first evidence that elderly 
cancer patients seemed to suffer from a more severe decline in thymic output and had a lower 
proportion of naïve CD8+ cells than age-matched controls. In addition, cancer patients had 
significantly shorter telomeres in their peripheral blood cells than  age-matched non-cancer patients. 
This result suggests the unpublished hypothesis – which would need to be tested in a larger study - 
that elderly people with shorter telomeres are at higher risk of developing cancer. It is noteworthy 
that the cancer patients’ thymic output decreased significantly with increasing age, while telomere 
length in the peripheral blood cells was unassociated with age. Finally, this preliminary study also 
confirms that there is no relationship between the geriatric phenotypes investigated by the CGA and 
these molecular markers of aging.  
Really, in the lack of molecular markers that estimate the biological age of single individuals, the 
CGA remain the only way of estimating the life-expectancy and the chemotherapy toxicity. 
Therefore, the second chapter of this thesis reported a prospective trials that was the first to validate 
in the oncological setting a standardized version of CGA to be used in further clinical trials, as 
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required by the International Society of Geriatric Oncology. In the present study the MPI retained in 
elderly patients with advanced cancer the same reliability and accuracy as reported in the original 
study by Pilotto et al. The results also suggested the possibility of creating a new, better-performing 
version of MPI by integrating it with the comorbidity severity index and the geriatric depression 
scale.  
Finally, the third challenge of the Geriatric Oncology is to validate a fast version of CGA that may 
be easily applied to elderly cancer patients in order to estimate the risk of chemotherapy toxicity 
before any treatment decision. For this purpose the Vulnerable Elders Survey – 13 by Mohile-Saliba 
seems to be the best option. The ability of VES-13 to predict chemotherapy toxicity in elderly 
cancer patients was tested in 4 italian, prospective trials that have been joined in a combined 
analysis. The patients identified as vulnerable by the VES-13 had a statistically significant higher 
risk of developing both hematological and non-hematological toxicity. These risk increases 
progressively with the aging of the population, particularly for haematological toxicity. 
In conclusion, the present thesis provided two important evidences:  
1. The physiology of ageing in cancer patients can be profitably studied by translational research, in 
order to suggest possible biological markers of cancer risk, cancer mortality or toxicity, to optimize 
the approach to cancer treatment in elderly patients. In this case, markers of immunesenescence and 
telomere length deserve to be tested in larger cohorts. If confirmed, they could be widely used in 
elderly general population to easily identify subjects who run an higher risk of developing cancer 
and optimize the resources for screening procedures.  
2. MPI seems to be the right candidate for the standardized geriatric assessment in the context of 
clinical trials, where specific geriatric endpoints are never currently used, as well as VES-13 
correctly estimates the risk of chemotherapy toxicity. With the awareness that geriatric assessment 
of cancer patients cannot relies on a single test, future studies should be planned with the aim of 
prospectively identifying which is the most appropriate geriatric instrument for any single aspect of 
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patient management (e.g. toxicity, overall survival, active life expectancy, or the quality of life) and 
clinical research.  
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